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ARTICLE

Proteomic and functional mapping of cardiac NaV1.5
channel phosphorylation sites

Phosphorylation of the voltage-gated Na+ (NaV) channel NaV1.5 regulates cardiac excitability, yet the phosphorylation sites
regulating its function and the underlying mechanisms remain largely unknown. Using a systematic, quantitative
phosphoproteomic approach, we analyzed NaV1.5 channel complexes purified from nonfailing and failing mouse left
ventricles, and we identified 42 phosphorylation sites on NaV1.5. Most sites are clustered, and three of these clusters are
highly phosphorylated. Analyses of phosphosilent and phosphomimetic NaV1.5 mutants revealed the roles of three
phosphosites in regulating NaV1.5 channel expression and gating. The phosphorylated serines S664 and S667 regulate the
voltage dependence of channel activation in a cumulative manner, whereas the nearby S671, the phosphorylation of which is
increased in failing hearts, regulates cell surface NaV1.5 expression and peak Na+ current. No additional roles could be assigned
to the other clusters of phosphosites. Taken together, our results demonstrate that ventricular NaV1.5 is highly
phosphorylated and that the phosphorylation-dependent regulation of NaV1.5 channels is highly complex, site specific, and
dynamic.

Introduction
Voltage-gated Na+ (NaV) channels are key determinants of myocardial excitability, and defects in NaV channel expression
or functioning in the context of inherited or acquired cardiac
disease increase the propensity to develop lethal arrhythmias
(Remme and Bezzina, 2010). Ventricular NaV channels, composed primarily of the NaV1.5 channel pore-forming subunit, in
association with several accessory/regulatory proteins, generate
the transient peak Na+ current (INa) responsible for the action
potential upstroke and rapid intercellular conduction. While
cardiac myocyte NaV channels inactivate quickly, there is a finite
probability (∼0.5%) of channels remaining open, resulting in the
late component of the Na+ current (INaL), which contributes to
determining action potential duration. In the ventricular myocardium, the NaV1.5 protein is subject to many post-translational
modifications, each of which fine-tunes channel expression and
functioning in various physiological and disease contexts. Among
the 11 different post-translational modifications previously shown
to regulate cardiac NaV1.5 channels, phosphorylation at serine,

threonine, and tyrosine residues is certainly the best characterized (reviewed in Marionneau and Abriel, 2015; Pei et al., 2016;
Yu et al., 2018; Plant et al., 2020).
A role for phosphorylation in regulating cardiac NaV1.5
channels was first suggested in a pioneering study demonstrating that β-adrenergic receptors couple to NaV channels not
only through a direct G protein pathway but also through an
indirect PKA-dependent pathway (Schubert et al., 1989). The
involvement of several additional kinases and phosphatases in
regulating INa and/or INaL later spotlighted the functional relevance of cardiac NaV1.5 channel phosphorylation. Perhaps most
strikingly, progress in mass spectrometry (MS)-based phosphoproteomic analyses recently buttressed the field by revealing the
existence of multiple phosphorylation sites on native ventricular
(Marionneau et al., 2012b; Burel et al., 2017) and heterologously
expressed (Herren et al., 2015) NaV1.5 channels. Yet, little is known
about the roles and detailed molecular mechanisms that underlie
phosphorylation-dependent regulation of cardiac NaV1.5 channels.

.............................................................................................................................................................................
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hot spots for regulation of both channel cell surface expression
and gating.

Materials and methods
Statement on the use of murine tissue
All investigations conformed to Directive 2010/63/EU of the
European Parliament, to the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of
Health (Publication No. 85-23, revised 1985), and to local institutional guidelines.
Animal model of heart failure
Heart failure was induced by TAC as described previously
(Toischer et al., 2013). 8-wk-old male C57BL/6J mice were
anesthetized using intraperitoneal injections of medetomidine
(0.5 mg/kg), midazolam (5 mg/kg), and fentanyl (0.05 mg/kg
body weight). A horizontal incision (1–1.5 cm) at the jugulum
was used to display the transverse aorta, and a 27-gauge needle
was tied against the aorta using a 6-0 nonabsorbable suture.
After removal of the 27-gauge needle, the skin was closed, and
the mice were kept on a heating plate until they recovered from
the anesthesia. Sham animals underwent the same procedure
except for the banding of the transverse aorta. At the end of the
surgery, anesthesia was antagonized using intraperitoneal injections of atipamezole (2.5 mg/kg), flumazenil (0.5 mg/kg), and
buprenorphine (0.1 mg/kg body weight). For analgesia, metamizole (1.33 mg/ml) was added to the drinking water 2 d before
surgery and was supplied for 7 d after operation. In addition,
buprenorphine (60 µg/kg body weight) was administered subcutaneously 1 h before surgery. A TAC with a mean gradient of
<5 mm Hg was deemed insufficient to induce heart failure, and if
observed, the animal was excluded from later analysis. Mice
were sacrificed 5 wk after TAC by cervical dislocation, and left
ventricles were harvested, flash frozen, and stored for further
analyses.
Mouse echocardiography
Transthoracic echocardiography was performed blinded before
and 5 wk after TAC using a Vevo 3100 system (VisualSonics)
equipped with a 30-MHz center frequency transducer, as described previously (Toischer et al., 2013). The animals were
initially anesthetized with 3% isoflurane, while temperature-,
respiration-, and electrocardiogram-controlled anesthesia was
maintained with 1.5% isoflurane. 2-D cine loops with frame rates
of >200 frames/s of a long-axis view and a short-axis view at the
midlevel of the papillary muscles, as well as M-mode loops of the
short-axis view, were recorded. Thicknesses of the anterior and
posterior walls of the left ventricle, the inner diameter of the left
ventricle (LVID), and the area of the left ventricular cavity were
measured in systole and diastole from the short-axis view according to standard procedures (Gao et al., 2011). Maximal left
ventricular length was measured from the long-axis view. Systolic and diastolic left ventricular volumes were calculated using
the area-length method, and the ejection fraction was derived.
Left ventricular mass (LVM) was calculated from anterior and
posterior wall thicknesses using Vevo LAB Software (VisualSonics).
Journal of General Physiology
https://doi.org/10.1085/jgp.202012646

Downloaded from http://rupress.org/jgp/article-pdf/153/2/e202012646/1407549/jgp_202012646.pdf by Washington University In St. Louis Libraries user on 26 March 2021

Phosphorylation of NaV1.5 channels has also recently been
suggested as an arrhythmogenic mechanism in heart failure
(Wagner et al., 2006; Maltsev et al., 2008; Koval et al., 2012; Aiba
et al., 2013; Toischer et al., 2013; Glynn et al., 2015). The NaV
channel defects associated with heart failure are most often
characterized by increased INaL and/or decreased INa, contributing to action potential prolongation and conduction slowing,
respectively (Zicha et al., 2004; Valdivia et al., 2005; Maltsev
et al., 2007; Xi et al., 2009; Aiba et al., 2013; Toischer et al., 2013).
The increase in INaL has reportedly been linked to the activation
of kinases, mainly the Ca2+/calmodulin-dependent protein kinase II (CaMKII; Wagner et al., 2006; Maltsev et al., 2008; Aiba
et al., 2013; Toischer et al., 2013), and several studies have focused on identifying the CaMKII-dependent NaV1.5 phosphorylation sites (Hund et al., 2010; Ashpole et al., 2012; Herren et al.,
2015; Burel et al., 2017). Notably, increased CaMKII-dependent
NaV1.5 phosphorylation at serine 571 has been reported and
suggested to increase INaL in nonischemic human heart failure
(Koval et al., 2012) and in animal models of heart disease (Koval
et al., 2012; Toischer et al., 2013; Glynn et al., 2015). Nevertheless, NaV1.5 channel phosphorylation may not be the sole
mechanism involved in the observed pathophysiological defects, as other evidence suggests roles for up-regulation of the
neuronal NaV1.1 (Xi et al., 2009; Mishra et al., 2015), NaV1.6 (Xi
et al., 2009), or NaV1.8 (Dybkova et al., 2018) channels. Intensive investigations were also undertaken to understand the
causes of the reduced INa; yet, the detailed underlying molecular mechanisms remain unclear. While most studies failed to
detect any changes in NaV1.5 transcript or total protein expression in failing human hearts (Kääb et al., 1998) or in animal
models of heart failure (Zicha et al., 2004; Valdivia et al., 2005),
several mechanisms have been suggested to contribute to reduced INa, including the generation of a C-terminal truncation
splicing variant switch in NaV1.5 transcripts (Shang et al., 2007;
Noyes et al., 2017), elevated NADH and reactive oxygen species
production (Liu et al., 2013), or increased intracellular Ca2+
concentration and subsequent increased expression of the E3
ubiquitin ligase Nedd4-2 (Luo et al., 2017). In line with reduced
INa, a recent study using high-resolution imaging and functional techniques showed a reduction in NaV1.5 cluster size and
a corresponding decreased number of open channels at the
lateral membranes of ventricular myocytes from mice subjected to transverse aortic constriction (TAC), without any
changes in NaV1.5 transcript or total protein expression (Rivaud
et al., 2017).
In this study, we investigated the patterns of phosphorylation
of native mouse left ventricular NaV1.5 channels and the
roles of identified phosphorylation sites in regulating NaV1.5
channel expression and functioning. Using quantitative MSbased phosphoproteomic analyses, we identified and quantified in situ the native phosphorylation sites of the NaV1.5 in a
mouse model of pressure overload–induced heart failure produced by TAC. By analyzing the expression and the functional
properties of phosphosilent and phosphomimetic NaV1.5 mutant channels in human embryonic kidney 293 (HEK-293) cells,
as well as simulating the consequences of phosphorylation on
NaV1.5 peptide segment expansion, we identified phosphorylation
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Pulsed-wave Doppler ultrasound was used to assess mean gradients
3 d after the TAC procedure.

Peptide preparation and isobaric labeling for liquid
chromatography (LC)-MS
The IP eluates were thawed on ice, reduced, and denatured by
heating for 10 min at 95°C. The Cys residues were alkylated with
iodoacetamide (10 mM) for 45 min at room temperature in the
dark. The peptides were prepared using a modification (Erde
et al., 2014) of the filter-aided sample preparation method
(Wiśniewski et al., 2009). After the addition of 300 µl of 100 mM
Tris buffer (pH 8.5) containing 8 M urea (UT buffer) and vortexing, the samples were transferred to YM-30 filter units
(MRCF0R030; EMD Millipore) and spun for 14 min at 10,000 rcf
(model 5424; Eppendorf). The filters were washed with 200 µl of
UT buffer, and the spin-wash cycle was repeated twice. The
samples were then exchanged into digest buffer with the addition of 200 µl of 50 mM Tris buffer, pH 8.0, followed by centrifugation (10,000 rcf for 10 min). After transferring the upper
filter units to new collection tubes, 80 µl of digest buffer were
added, and the samples were digested with trypsin (1 µg) for 4 h
at 37°C. The digestion was continued overnight after adding
another aliquot of trypsin. The filter units were then spun for
10 min (10,000 rcf) in an Eppendorf microcentrifuge. The filter
was washed with 50 µl of Tris buffer (100 mM, pH 8.0), followed
by centrifugation. The digests were extracted three times with
1 ml ethyl acetate and acidified to 1% trifluoroacetic acid (TFA)
using a 50% aqueous solution. The pH was <2.0 by checking
Lorenzini et al.
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Nanoscale LC-MS
The samples in FA (1%) were loaded (2.5 µl) onto a 75-µm ID ×
50-cm Acclaim PepMap 100 C18 RSLC column (Thermo Fisher
Scientific) on an EASY nano-LC (Thermo Fisher Scientific). The
column was equilibrated using constant pressure (700 bar) with
20 µl of solvent A (0.1% FA). The peptides were eluted using the
following gradient program with a flow rate of 300 nl/min and
using solvents A and B (acetonitrile with 0.1% FA): solvent A
containing 5% B for 1 min, increased to 25% B over 87 min, to
35% B over 40 min, to 70% B in 6 min and constant 70% B for
6 min, to 95% B over 2 min and constant 95% B for 18 min. The
data were acquired in data-dependent acquisition mode. The
mass spectrum of peptide precursors (MS1) scans were acquired
with the Orbitrap mass analyzer over mass-to-charge ratio =
375–1,500 and with resolution set to 70,000. 12 data-dependent
high-energy collisional dissociation spectra (MS2) were acquired from each MS1 scan with a mass resolving power set to
35,000, a range of mass-to-charge ratio = 100–1,500, an isolation
width of 2 Th, and a normalized collision energy setting of 32%.
The maximum injection time was 60 ms for parent ion analysis
and 120 ms for product ion analysis. The ions that were selected
for MS2 were dynamically excluded for 20 s. The automatic
gain control was set at a target value of 3e6 ions for MS1 scans
and 1e5 ions for MS2. Peptide ions with charge states of 1 or ≥7
were excluded for higher-energy collision–induced dissociation
acquisition.
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Immunoprecipitation (IP) of NaV channel complexes
Flash-frozen left ventricles from four sham and five TAC mice
were homogenized individually in ice-cold lysis buffer containing 20 mM HEPES (pH 7.4), 150 mM NaCl, 0.5% amidosulfobetaine, 1× complete protease inhibitor cocktail tablet,
1 mM PMSF, 0.7 µg/ml pepstatin A (Thermo Fisher Scientific),
and 1× Halt phosphatase inhibitor cocktail (Thermo Fisher Scientific) as described previously (Marionneau et al., 2012b). All
reagents were from Sigma-Aldrich unless otherwise noted. After
15-min rotation at 4°C, 8 mg of the soluble protein fractions were
precleared with 200 µl of protein G-magnetic Dynabeads
(Thermo Fisher Scientific) for 1 h and subsequently used for IPs
with 48 µg of an anti-NaVPAN mouse mAb (mαNaVPAN, S8809;
Sigma-Aldrich) raised against the SP19 epitope (Vassilev et al.,
1988) located in the third intracellular linker loop and common
to all NaV channel pore-forming subunits. Prior to the IP, antibodies were cross-linked to 200 µl of protein G-magnetic Dynabeads using 20 mM dimethyl pimelimidate (Thermo Fisher
Scientific; Schneider et al., 1982). Protein samples and antibodycoupled beads were mixed for 2 h at 4°C. Magnetic beads were
then collected and washed rapidly four times with ice-cold lysis
buffer, and isolated protein complexes were eluted from the
beads in 1× SDS sample buffer (Bio-Rad Laboratories) at 60°C for
10 min. 99% of the immunoprecipitated mouse left ventricular
NaV channel protein complexes were analyzed by MS, and the
remaining 1% were used to verify IP yields by Western blotting
using a rabbit polyclonal anti-NaV1.5 antibody (RbαNaV1.5, 1:1,000,
ASC-005; Alomone Laboratories).

with pH paper. The solid-phase extraction of the peptides was
performed using porous graphite carbon microtips (Chen et al.,
2012). The peptides were eluted with 60% acetonitrile in 0.1%
TFA and pooled for drying in a Speed-Vac (model Savant DNA
120 concentrator; Thermo Fisher Scientific) after adding TFA to
5%. The peptides were dissolved in 20 µl of 1% acetonitrile in
water. An aliquot (10%) was removed for quantification using
the Pierce Quantitative Fluorometric Peptide Assay Kit (23290;
Thermo Fisher Scientific). The remainder of the peptides from
each IP sample (∼0.5–3.5 µg) and 1.16 µg of reference pool
peptide were transferred into a new 0.5-ml Eppendorf tube,
dried in the Speed-Vac, and dissolved in 12 µl HEPES buffer (100
mM, pH 8.0, H3537; Sigma-Aldrich).
The samples were labeled with tandem mass tag (TMT) reagents (TMT11; Thermo Fisher Scientific) according to the
manufacturer’s protocol. The labeled samples were pooled,
dried, and resuspended in 120 µl of 1% formic acid (FA). The
TMT11-labeled sample was desalted as described above for the
unlabeled peptides. The eluates were transferred to autosampler
vials (200046; SUN-SRi), dried, and stored at −80°C for capillary
LC interfaced to a mass spectrometer (nanoscale LC-MS).

MS data analysis
Peptide identification from raw MS data was performed using
PEAKS Studio 8.5 (Bioinformatics Solutions Inc.; Zhang et al.,
2012). The Uni-mouse-Reference-20131008 protein database
was used for spectral matching. The precursor and product ion
mass tolerances were set to 20 ppm and 0.05 D, respectively,
and the enzyme cleavage specificity was set to trypsin, with a
maximum of three missed cleavages allowed. Carbamidomethylation
Journal of General Physiology
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Plasmids
The NaV1.5 phosphomutant constructs were generated by mutating
the serine(s)/threonine(s) to alanine(s) (A) or glutamate (E), as well
as aspartate(s) (D) in the NaV1.5-S664-671D quadruple phosphomimetic channel, by site-directed mutagenesis of a pCI-NaV1.5
plasmid containing the human NaV1.5 hH1C cDNA (Makielski et al.,
2003; National Center for Biotechnology Information reference
sequence NM_000335) using the QuikChange II XL Site-Directed
Mutagenesis Kit (Agilent) or the Q5 Site-Directed Mutagenesis Kit
(New England Biolabs). The mutated constructs were then digested
with restriction endonucleases to excise the mutated fragments,
which were then subcloned into the original pCI-NaV1.5 plasmid.
The human NaVβ1 (NM_001037; a gift from A.L. George, Department of Pharmacology, Northwestern University, Evanston, IL)
cDNAs were subcloned into pRc/cytomegalovirus. All constructs
were sequenced to ensure that no unintentional mutations were
introduced.
Culture and transient transfections
HEK-293 cells were maintained in Dulbecco’s modified Eagle’s
medium (Thermo Fisher Scientific), supplemented with 10%
Lorenzini et al.
Mapping of cardiac NaV1.5 channel phosphorylation sites

FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin in a 37°C,
5% CO2, 95% air incubator. Cells were transiently transfected at
70–80% confluence in 35-mm dishes with 0.6 µg of the WT or
phosphomutant NaV1.5 plasmid and 1.2 µg of the NaVβ1 plasmid
using 2 µl Lipofectamine 2000 (Thermo Fisher Scientific) following the manufacturer’s instructions. For whole-cell recordings, transfections also contained 0.2 µg of the pEGFP plasmid
(enhanced GFP plasmid; Clontech), and EGFP expression served
as a marker of transfection. The absolute amounts of the various
constructs were calculated, and the empty pcDNA3.1 plasmid
was used as a filler plasmid to keep the total DNA constant at
2 µg in each transfection.
Electrophysiological recordings
Whole-cell NaV currents were recorded at room temperature
from transiently transfected HEK-293 cells using an Axopatch
200A amplifier (Axon Instruments/Molecular Devices) 48 h
after transfection. Voltage-clamp protocols were applied using
the pClamp 10.2 software package (Axon Instruments) interfaced to the electrophysiological equipment using a Digidata
1440A digitizer (Axon Instruments). Current signals were filtered at 10 kHz before digitization at 50 kHz and storage. Patchclamp pipettes were fabricated from borosilicate glass (OD, 1.5
mm; ID, 0.86 mm; Sutter Instrument) using a P-97 micropipette
puller (Sutter Instrument), coated with wax, and fire polished to
a resistance between 1.5 and 2.5 MΩ when filled with internal
solution. The internal solution contained (in mM) 5 NaCl, 115
CsF, 20 CsCl, 10 HEPES, and 10 EGTA (pH 7.35 with CsOH, ∼300
mosM). The external solution contained (in mM) 10 NaCl (20
NaCl for analysis of single phosphomutants), 103 CsCl, 25 TEACl, 10 HEPES, 5 glucose, 1 CaCl2, and 2 MgCl2 (pH 7.4 with CsOH,
∼300 mosM). All chemicals were purchased from SigmaAldrich. After establishing the whole-cell configuration, 3 min
were allowed to ensure stabilization of voltage-dependence of
activation and inactivation properties, at which time 25-ms
voltage steps to ±10 mV from a holding potential (HP) of
−70 mV were applied to allow measurement of whole-cell Cm,
input, and series resistances. Only cells with access resistance <7
MΩ were used, and input resistances were typically >5 GΩ.
After compensation of series resistance (80%), the membrane
was held at an HP of −120 mV, and the voltage-clamp protocols
were performed as indicated below. Leak currents were always
<200 pA at HP (−120 mV) and were corrected offline. Cells exhibiting peak current amplitudes <500 or >5,000 pA were excluded from analyses of biophysical properties because of leak or
voltage-clamp issues, respectively, but were conserved in analyses of peak current density to avoid bias in evaluation of current densities.
Data were compiled and analyzed using ClampFit 10.2 (Axon
Instruments), Microsoft Excel, and Prism (GraphPad Software).
Whole-cell Cm values were determined by analyzing the decays
of capacitive transients elicited by brief (25-ms) voltage steps to
±10 mV from the HP (−70 mV). Input resistances were calculated
from the steady-state currents elicited by the same ±10-mV steps
(from the HP). Series resistances were calculated by dividing the
decay time constants of the capacitive transients (fitted with
single exponentials) by the Cm. To determine peak Na+ I-V
Journal of General Physiology
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(Cys) and TMTs (Lys and/or peptide N terminus) were
treated as fixed modifications, while oxidation (Met),
pyroglutamination (Gln), deamidation (Asn and/or Gln),
methylation (Lys and/or Arg), dimethylation (Lys and/or
Arg), acetylation (Lys), and phosphorylation (Ser, Thr, and/
or Tyr) were considered variable modifications. The definitive annotation of each NaV1.5 phosphopeptide–spectrum
match was obtained by manual verification and interpretation. The phosphorylation site assignments were based on
the presence or absence of the unphosphorylated and phosphorylated b and y ions flanking the site(s) of phosphorylation,
ions referred to as “site-discriminating ions” throughout this
study. When site-discriminating ions were not all detected, the
assignment of phosphorylation sites was narrowed down to
several possibilities by elimination (for example, pS1056 and/or
pT1058). Representative MS/MS spectra, PEAKS −10lgP scores,
mass errors of parent ions (in ppm), and charge state confirmations of site-discriminating b and y ions are presented in
Table 2, Table S3, and Data S1.
The protein and peptide relative abundances in TAC versus
sham mαNaVPAN-IPs were calculated using quantification of
TMT reporter ions. Reporter ion intensities in each TMT channel were normalized to the mean reporter ion intensities of
NaV1.5-derived peptides (normalization to spike) to correct for
differences in IP yields and technical variabilities. Normalization factors are presented in Fig. S1 B. Quantification values of
each peptide–spectrum match were exported into Excel, and the
mean peptide abundance ratios were calculated from the abundance
ratios of all manually verified peptide–spectrum matches assigning
to the phosphorylation site(s) of interest. Label-free quantitative
analysis of the areas of extracted MS1 chromatograms of phosphorylated and nonphosphorylated peptide ions covering the phosphorylation site(s) of interest was used to evaluate the proportion of
phosphorylated to nonphosphorylated peptides at each position, as
well as the relative abundances of phosphopeptides.
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exhibiting peak current amplitudes >4,000 pA were used (those
with peak currents <4,000 pA did not show measurable INaL),
and cells with difference in leak current amplitudes before and
after TTX application >5 pA at −20 mV (calculated from leak
currents at −120 mV) were excluded from analyses. TTXsensitive currents from individual cells were determined by
offline digital subtraction of average leak-subtracted currents
obtained from five recordings in the absence and in the presence
of TTX after achieving steady state. The amplitude of TTXsensitive INaL was defined as the steady-state current amplitude (A0) obtained by fitting the inactivation decay of macroscopic TTX-sensitive current with the double-exponential
function I(t) = Afast × exp (−t/τfast) + Aslow × exp (−t/τslow) + A0.
For each cell, the TTX-sensitive INaL amplitude was normalized
to the peak INa amplitude and expressed as a percentage of the
peak INa.
Cell surface biotinylation and Western blot analyses
Surface biotinylation of HEK-293 cells was completed as described previously (Marionneau et al., 2012a). Briefly, cells were
incubated with the cleavable EZ-Link Sulfo-NHS-SS-Biotin
(0.5 mg/ml; Thermo Fisher Scientific) in ice-cold PBS (pH 7.4)
for 30 min at 4°C. Free biotin was quenched with Tris-saline
(10 mM Tris [pH 7.4], 120 mM NaCl), and detergent-soluble cell
lysates were prepared. Biotinylated cell surface proteins were
affinity purified using NeutrAvidin-conjugated agarose beads
(Thermo Fisher Scientific), and purified cell surface proteins
were analyzed by Western blot using the mαNaVPAN antibody
(1:2,000, S8809; Sigma-Aldrich), the anti–transferrin receptor
mouse mAb (TransR, 1:1000, Thermo Fisher Scientific), and the
anti-glyceraldehyde 3-phosphate dehydrogenase mouse mAb
(anti-GAPDH, 1:100,000; Santa Cruz Biotechnology). Bound
primary antibodies were detected using horseradish peroxidase–
conjugated goat anti-mouse secondary antibodies (Cell Signaling
Technology), and protein signals were visualized using the SuperSignal West Dura Extended Duration Substrate (Thermo Fisher
Scientific). Bands corresponding to NaV1.5 were normalized
to bands corresponding to TransR from the same sample.
NaV1.5 phosphomutant protein expression (total or cell surface)
is expressed relative to NaV1.5-WT protein expression (total or
cell surface).
Molecular simulations
Molecular simulations were performed with the CAMPARI
software package (Vitalis and Pappu, 2009b) using the ABSINTH
implicit solvation model (Vitalis and Pappu, 2009a) and parameters from the all-atom optimized potentials for liquid
simulations force field. Markov chain Metropolis Monte Carlo
moves sampled the conformational space of each protein segment. To mimic a 5 mM NaCl concentration, neutralizing and
excess Na+ and Cl− ions were modeled explicitly with the protein
segments in spherical droplets of (5 × number of residues) Å
radius. 10 simulation runs were performed for each sequence
construct, and the average of these 10 runs was then plotted. The
simulations denoted as EV (excluded volume) and FRC (Flory
random coil) are reference models. In the EV limit, the only
interactions considered are the pairwise repulsions. In the FRC
Journal of General Physiology
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relationships, currents were elicited by 50-ms depolarizing
pulses to potentials ranging from −80 to +40 mV (presented at
5-s intervals in 5-mV increments) from an HP of −120 mV. Peak
current amplitudes were defined as the maximal currents
evoked at each voltage. Current amplitudes were leak corrected
and normalized to the Cm, and current densities are presented.
To analyze voltage dependence of current activation properties, G values were calculated, and G-V relationships were
fitted with the Boltzmann equation G = Gmax/{1 + exp[−(Vm −
V1/2) / k]}, in which V1/2 is the membrane potential of halfactivation and k is the slope factor. The time courses of inactivation of macroscopic currents were fitted with biexponential
functions, I(t) = Afast × exp(−t/τfast) + Aslow × exp(−t/τslow) + A0,
in which Afast and Aslow are the amplitudes of the fast and slow
inactivating current components, respectively, and τfast and τslow
are the decay time constants of Afast and Aslow, respectively. A
standard two-pulse protocol was used to examine the voltage
dependences of steady-state inactivation. From an HP of −120
mV, 1-s conditioning pulses to potentials ranging from −120 to
−45 mV (in 5-mV increments) were followed by 20-ms test
depolarizations to −20 mV (interpulse intervals were 5 s). Current amplitudes evoked from each conditioning voltage were
measured and normalized to the maximal current (Imax) evoked
from −120 mV, and normalized currents were plotted as a
function of the conditioning voltage. The resulting steady-state
inactivation curves were fitted with the Boltzmann equation
I = Imax/{1 + exp[(Vm − V1/2) / k)]}, in which V1/2 is the membrane potential of half-inactivation and k is the slope factor. To
examine the rates of recovery from inactivation, a three-pulse
protocol was used. Cells were first depolarized to −20 mV (from
an HP of −120 mV) to inactivate the channels and subsequently
repolarized to −120 mV for varying times (ranging from 1 to 200
ms), followed by test depolarizations to −20 mV to assess the
extent of recovery (interpulse intervals were 5-s). The current
amplitudes at −20 mV, measured following each recovery period, were normalized to the maximal current amplitude and
plotted as a function of the recovery time. The resulting plot was
fitted with a single exponential function I(t) = A × [1 − exp(−t/
τrec)] to determine the recovery time constant. For each of these
biophysical properties, data from individual cells were first fitted and then averaged.
The currents generated on expression of each phosphosilent
and phosphomimetic NaV1.5 mutant were recorded and compared with currents generated by the NaV1.5-WT construct obtained on the same days of patch-clamp analyses. The densities
and properties of NaV1.5-WT currents in each dataset were
similar, and, for the sake of clarity, a single representative
NaV1.5-WT channel dataset was chosen and presented in Fig. S3
and Tables 3 and 4.
In experiments aimed at recording the tetrodotoxin (TTX)sensitive INaL, cells were bathed in external solution containing
(in mM) 120 NaCl, 25 TEA-Cl, 10 HEPES, 5 glucose, 1 CaCl2, and
2 MgCl2 (pH 7.4 with CsOH, ∼300 mosM). Repetitive 350-ms
test pulses to −20 mV from an HP of −120 mV (at 5-s intervals)
were applied to cells to record INa in the absence of TTX. Cells
were then superfused locally with the external solution supplemented with 30 µM TTX (Bio-Techne SAS). Only cells
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limit, conformations are constructed by randomly sampling
residue-specific backbone dihedral angles. Three EV and three
FRC simulation runs were performed for each protein segment,
and the averages were plotted.

Online supplemental material
The supplemental figures and tables show multiple pieces of raw
or analyzed data to complement the main figures as explicated in
the text. Fig. S1 shows IP yields and relative quantification of
NaV1.5 peptide abundances from sham and TAC mouse left
ventricles. Fig. S2 shows conservation of phosphorylation sites
in mouse and human NaV1.5. Fig. S3 shows distributions and
mean ± SEM membrane potentials for half-activation and halfinactivation, peak INa densities, and time constants of recovery
from inactivation of WT and mutant NaV1.5 channels. Fig. S4
shows distributions and mean ± SEM of TTX-sensitive INaL
densities of quadruple S664-671 and simple S671 NaV1.5 phosphomutants. Data S1 shows representative MS/MS spectra
corresponding to the phosphopeptides enabling the best phosphorylation site assignment(s) for each phosphorylation site.
Table S1 lists echocardiographic parameters of sham and TAC
mice before and 5 wk after surgery. Table S2 summarizes
NaV1.5 phosphorylation sites identified in the present and
previous studies. Table S3 lists phosphorylation sites, phosphopeptides, and site-discriminating ions identified in coimmunoprecipitated NaV α subunits from sham and TAC mouse
left ventricles using MS.

Results
Purification and characterization of NaV channel complexes
from sham and TAC mouse left ventricles
NaV channel complexes from four sham-operated and five TAC
mouse left ventricles were purified by IP using an mαNaVPAN
and characterized using quantitative isobaric TMT-based
analysis. As illustrated in Table S1, and consistent with previous findings (Toischer et al., 2013), the echocardiographic
analysis confirmed increased LVMs (LVM/body weight ratios),
reduced ejection fractions, but unaltered left ventricular enddiastolic diameters (LVID;d) 5 wk after the TAC surgery, demonstrating left ventricular concentric hypertrophy and systolic
contractile dysfunction or heart failure in the TAC animals.
Western blot analyses of total lysates showed similar total NaV1.5
protein expression in sham and TAC left ventricles, which resulted in similar NaV1.5 IP yields in the nine samples (Fig. S1 A).
Isolated NaV channel complexes were then digested with trypsin,
Lorenzini et al.
Mapping of cardiac NaV1.5 channel phosphorylation sites

Identification and quantification of 42 NaV1.5 phosphorylation
sites in sham and TAC mouse left ventricles
The phosphoproteomic analysis of the mαNaVPAN-IPs from
sham and TAC mouse left ventricles allowed the unambiguous
identification of 42 native phosphorylation sites in the NaV1.5
protein, 19 of which have never, to our knowledge, been previously described (Figs. 1 A and 2). Table 2 lists the phosphopeptides enabling the best phosphorylation site assignment(s)
for each phosphorylation site, and corresponding MS/MS
spectra are presented in Data S1. Table S2 lists these 42 phosphorylation sites with all the other phosphorylation sites identified so far on the mouse and/or human NaV1.5 protein,
whether by using MS, in silico, and/or in vitro analyses. Interestingly, the vast majority of these 42 phosphorylation sites
are clustered, with the first intracellular linker loop of NaV1.5
revealed as a hot spot for phosphorylation, with a total of 21
sites identified. Further label-free quantitative analysis of the
areas of extracted MS1 peptide ion chromatograms revealed
large differences in the relative abundance of the individual
Journal of General Physiology
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Statistical analyses
Results are expressed as means ± SEMs. Data were first tested
for normality using the D’Agostino and Pearson normality test.
Depending on the results of normality tests, statistical analyses
were then performed using the Mann-Whitney nonparametric
test, Kruskal-Wallis one-way ANOVA followed by Dunn’s posthoc test, or one-way ANOVA followed by Dunnett’s post-hoc
test, as indicated in figures and tables. All these analyses, as
well as plots and graphs, were performed using Prism software
(GraphPad Software).

and peptide mixtures were labeled with different TMTs and
combined in the same TMT set for multiplexed MS/MS analysis
(Fig. 1 E). As illustrated in Table 1, the NaV1.5 protein was the
most represented protein in the mαNaVPAN-IPs, with 310
unique and NaV1.5-specific peptides identified and 56% amino
acid sequence coverage (70% with the transmembrane domains
removed; Fig. 2).
Consistent with the homogeneous yields in the NaV1.5 IP, the
relative abundance of the NaV1.5 peptides detected by MS in the
nine samples was similar and used for normalization of each
single protein and peptide abundance (Fig. S1 B). Accordingly,
the distribution of normalized abundance ratios of NaV1.5 peptides (in log2) in TAC versus sham mαNaVPAN-IPs was centered on zero (Fig. S1 C). Altogether, therefore, these observations
attest to a high reproducibility across biological replicates and
a low technical variability inherent to experimental procedures. Of note, and as described previously (Makielski et al.,
2003), several NaV1.5 peptides differing by the presence (1079QQESQVVSGGHEPPQEPR, Q1080 variant) or absence (1077SKQESQVVSGGHEPPQEPR and 1078-KQESQVVSGGHEPPQEPR,
Q1080del variant) of a glutamine (Q) at position 1080 were
detected (Table 1 and Fig. 2), reflecting the expression of
two distinct Na V1.5 variants in adult mouse left ventricles;
Q1080del corresponds to the commonly reported hH1C variant.
The identification of additional, nondiscriminating peptides
(1079-QESQVVSGGHEPPQEPR and 1079-QESQVVSGGH), which
could arise from either variant, however, prevented us from
quantifying the relative abundance of the two NaV1.5 variants.
These analyses also allowed the identification of eight additional
NaV channel pore-forming subunits, among which NaV1.4 is the
most abundant, with 86 unique NaV1.4-specific peptides detected (Table 1). In addition, several previously identified NaV1.5
channel associated/regulatory proteins, including calmodulin,
the VY variant of fibroblast growth factor homologous factor
2 (FHF2-VY) and ankyrin-G, were detected, with no significant
differences in abundance between sham and TAC mαNaVPANIPs (Table 1).
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Figure 1. Localization and quantification of 42 MS-identified NaV1.5 phosphorylation sites in mαNaVPAN-IPs from sham and TAC mouse left ventricles (LVs). (A) Schematic representation of phosphorylation sites on the NaV1.5 protein (UniProt reference sequence K3W4N7). Two phosphorylation site
locations are possible at amino acids S1056-T1058. (B) The areas of extracted MS1 ion chromatograms, corresponding to MS2 spectra assigning phosphorylated (in red) and nonphosphorylated (in white) NaV1.5 peptides at indicated phosphorylation site(s), in mαNaVPAN-IPs from sham and TAC LVs are
indicated. No red color is visible for the phosphorylated peptide at position T1809, because this phosphopeptide area is very small (area = 80,291 arbitrary unit)
relative to the areas of the nonphosphorylated peptides (areas = 80,060,220 arbitrary unit). (C) The areas of extracted MS1 ion chromatograms, corresponding
to MS2 spectra assigning phosphorylated peptides at indicated phosphorylation site(s), in mαNaVPAN-IPs from sham and TAC LVs are indicated. The brackets
indicate the subgroups of phosphorylation sites analyzed in B. Independent quantification of S459 and S460 phosphorylated peptides was not possible,
because localization of the phosphorylation site in most of the phosphorylated peptides could not be discriminated. Similar to B, no red bar is visible for the
phosphorylated peptide at position T1809, because this phosphopeptide area is very small (area = 80,291 arbitrary unit), relative to the areas of the other
phosphorylated peptides. (D) Distributions and mean ± SEM relative abundances of individual NaV1.5 phosphopeptides allowing assignments of indicated
phosphorylation site(s), as well as of corresponding nonphosphorylated (NP) peptides, in TAC LV (n = 5, in black) versus sham LV (n = 4, in white)
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mαNaVPAN-IPs were obtained using TMT reporter ion intensities. The relative abundances of NaV1.5 phosphopeptides exhibiting phosphorylation(s) on serine
671 (S671; n = 12 peptides) alone or in combination with serine 664 (S664 + S671; n = 9 peptides) or serine 667 (S667 + S671; n = 7 peptides) are increased (**,
P < 0.01; ***, P < 0.001; Mann-Whitney test) in TAC LV versus sham LV mαNaVPAN-IPs. (E) Experimental workflow used in the study. Once immunoprecipitated using the mαNaVPAN antibodies, the NaV channel complexes from sham and TAC mouse LVs were labeled individually with different TMT10
tags and combined in the same TMT set for multiplexed LC-MS/MS analysis. NaV1.5 phosphorylation sites were identified, quantified, and analyzed by clusters
in whole-cell voltage-clamp recordings in HEK-293 cells.

Functional mapping of NaV1.5 channel
phosphorylation clusters
The identification of several clusters of phosphorylation sites on
NaV1.5 suggests that these sites may be involved in the coordinated regulation of channel expression and/or function. Of the
eight clusters of phosphorylation identified in the mouse NaV1.5
protein, seven are conserved in the human NaV1.5 protein sequence; only the mouse T1105 is not conserved (Fig. S2). To investigate the functional roles of these (seven) phosphorylation
clusters, phosphosilent and phosphomimetic NaV1.5 channel
constructs in the human NaV1.5 hH1C cDNA sequence were
generated, transiently expressed with the NaVβ1 channel subunit
in HEK-293 cells, and characterized in whole-cell voltage-clamp
recordings. In the phosphosilent constructs, mutations were introduced to replace serines/threonines (S/T) with alanines (A),
Lorenzini et al.
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whereas in the phosphomimetic constructs, mutations were introduced to substitute glutamates (E) for serines/threonines, to
mimic phosphorylation.
As illustrated in Fig. 3 B, these whole-cell voltage-clamp
analyses demonstrated that the voltage dependence of activation of the NaV1.5-S664-671A quadruple phosphosilent channels,
in which all four of S664, S667, T670, and S671 are mutated to
alanines, is significantly (P < 0.001) shifted toward depolarized
potentials compared with WT channels (see distributions, detailed properties, and statistics in Fig. S3 A and Table 3). The
activation curve of the NaV1.5-S664-671E quadruple phosphomimetic channel was also significantly (P < 0.001) shifted, although to a lesser extent, when compared with the phosphosilent
channel. Together, therefore, these findings suggest that the S664671 cluster is phosphorylated in HEK-293 cells and that disruption
of phosphorylation at these sites shifts the voltage dependence of
channel activation toward depolarized potentials. To further
support the role of phosphorylation in this effect, the quadruple
aspartate (D) phosphomimetic channel, NaV1.5-S664-671D, was
generated, and analysis of voltage dependence of channel activation demonstrated no differences when compared with the WT
channel (Fig. 3 B, Fig. S3 A, and Table 3). Consequent to these
effects, the time to peak INa (Fig. 3 D), as well as the inactivation
time constants, τfast and τslow (Fig. 3, E and F), of the NaV1.5-S664671A and NaV1.5-S664-671E quadruple phosphomutant channels
were shifted toward depolarized potentials compared with the WT
NaV1.5 and the NaV1.5-S664-671D quadruple phosphomimetic
channels, until reaching full activation at ∼0 mV. In addition,
the peak INa density of the NaV1.5-S664-671E quadruple phosphomimetic channel was significantly (P < 0.05 at −20 mV)
reduced compared with the WT channel, whereas no significant changes were observed with the NaV1.5-S664-671A
and NaV1.5-S664-671D quadruple phosphomutant channels
(Fig. 3 C; see distributions at −20 mV and statistics in Fig. S3
B and Table 3). Importantly, however, evaluation and comparison of the peak INa densities of these four channel constructs is impeded by the differences in voltage dependence
of activation, and no significant differences in peak I Na
densities (at −20 or 0 mV) or maximal Na + G values (data
not shown) were observed for the Na V1.5-S664-671D, compared with WT, channels. Finally, the voltage dependence of
steady-state inactivation (Fig. 3 B, Fig. S3 C, and Table 3) and
the kinetics of recovery from inactivation (Fig. S3 D and
Table 3) of the Na V1.5-S664-671A and NaV1.5-S664-671E
quadruple phosphomutant channels were similar to those of
the WT channels. Additionally, and to our surprise, no differences in current densities, in the kinetics or voltage dependences of current activation and inactivation, or in the
kinetics of recovery from inactivation were observed for
Journal of General Physiology
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phosphopeptides and the existence of three highly phosphorylated clusters at positions S457-S460, S483-T486, and
S664-S671 (Fig. 1 B). In addition, and in contrast to the other
phosphorylation sites, the phosphorylated peptides assigning
these three phosphorylation clusters are more abundant than
their nonphosphorylated counterparts, suggesting that these
sites are mostly phosphorylated in native NaV1.5 channels in
WT mouse left ventricles. Looking into the detailed quantification of single phosphorylation sites inside each of these
clusters, however, major differences in phosphopeptide
abundance are evident (Fig. 1 C). This is the case, for example, of phosphorylation at S664 or S667, which is ∼10fold more abundant than at residues T670 or S671.
To determine whether phosphorylation of NaV1.5 is regulated
in heart failure, the relative abundance of each NaV1.5 phosphopeptide in TAC versus sham mαNaVPAN-IPs was calculated
using the relative abundance of TMT reporter ions. As illustrated in Fig. 1 D, peptides exhibiting phosphorylation(s) on
serine 671 (S671) alone or in combination with serine 664 (S664 +
S671) or serine 667 (S667 + S671) are significantly more abundant
in the TAC than in the sham mαNaVPAN-IPs. The relative
abundance of their nonphosphorylated counterparts, however,
is similar in sham and TAC mαNaVPAN-IPs. None of the other
NaV1.5 phosphopeptides showed any significant differences in
the sham and TAC mαNaVPAN-IPs (Table 2). In addition to
NaV1.5, four phosphorylation sites on NaV1.4 and one on NaV1.3
could also be detected (Table S3 and Data S1). Taken together,
these quantitative phosphoproteomic analyses identified 42
native phosphorylation sites on NaV1.5, among which 3 clusters
of phosphorylation in the first loop of the channel are highly
phosphorylated in mouse left ventricles and one serine at position 671 shows increased phosphorylation in TAC mouse left
ventricles.
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Table 1. Proteins identified in immunoprecipitated NaV channel complexes from sham and TAC mouse left ventricles using MS
UniProt
accession
number

No. of
exclusive
unique
peptides

Percentage
amino acid
sequence
coverage

TAC/
sham
ratio

Protein

UniProt
accession
number

No. of
exclusive
unique
peptides

Percentage
amino acid
sequence
coverage

TAC/
sham
ratio

NaV1.5
(Q1080)

K3W4N7

310

56%

1.0

N-cadherin

P15116

13

24%

0.8

NaV1.5
(Q1080del)

Q9JJV9

NaV1.4

G3X8T7

86

40%

0.8

Plakophilin-2

Q9CQ73

13

20%

0.7

NaV1.3

A2ASI5

24

17%

0.9

Plakophilin-1

P97350

5

8%

0.8

NaV1.8

Q6QIY3

13

9%

0.9

Telethonin

O70548

5

44%

0.8

NaV1.7

Q62205

3

2%

0.7

Desmoglein-2

O55111

13

19%

0.7

NaV1.9

Q9R053

1

1%

1.2

Flotillin-1

O08917

22

59%

0.9

NaV1.1

A2APX8

1

0.5%

1.3

Flotillin-2

Q60634

21

54%

0.8

NaV1.2

B1AWN6

1

0.5%

1.2

14-3-3 zeta/
delta

P63101

5

27%

0.9

NaV1.6

F6U329

1

0.6%

1.0

14-3-3 epsilon P62259

3

17%

1.0

NaVβ4

Q7M729

11

44%

0.7

14-3-3 gamma P61982

3

14%

1.0

NaVβ1

P97952

9

41%

1.0

14-3-3 beta/
alpha

Q9CQV8

1

6%

1.1

NaVβ2

Q56A07

6

37%

0.8

14-3-3 sigma

O70456

1

3%

0.9

Calmodulin

Q3UKW2

12

53%

0.8

Slmap

Q3URD3

1

1%

1.1

FHF2-VY

P70377

37

84%

0.8

αB-Crystallin

P23927

14

71%

0.7

FHF4

P70379

1

7%

0.7

Cx43

P23242

15

50%

0.7

Ankyrin-G

G5E8K5

47

32%

1.0

Kir2.1

P35561

3

11%

0.8

Ankyrin-R

Q02357

2

2%

1.0

CaMKIIγ

Q923T9

11

26%

0.8

Ankyrin-B

S4R245

1

0.4%

0.8

CaMKIIδ

E9Q1T1

2

6%

1.1

Dystrophin

P11531

88

29%

0.9

CaMKIIα

P11798

2

4%

0.8

α1Syntrophin

A2AKD7

20

53%

0.8

CaMKIIβ

Q5SVI2

1

3%

0.9

β2Syntrophin

Q61235

19

35%

0.9

PKA, catalytic
subunit, α

P05132

2

9%

1.0

α-Actinin-2

Q9JI91

50

60%

0.5

PKAβ-2

Q6PAM0

1

4%

1.1

Caveolin-1

P49817

6

39%

0.8

PKCβ

P68404

2

3%

1.6

Caveolin-2

Q9WVC3

3

28%

0.9

Fyn

P39688

1

2%

1.1

Caveolin-3

P51637

2

11%

0.8

PP2A-C

P63330

1

3%

1.1

Vinculin

Q64727

25

29%

0.7

The numbers of exclusive unique peptides, the percentage amino acid sequence coverages, and the fold change abundance ratios in TAC left ventricle (n = 5)
versus sham left ventricle (n = 4) mαNaVPAN-IPs for each identified protein are presented. No significant differences in protein abundance were observed
between TAC and sham IPs. Cx, connexin; FHF, fibroblast growth factor homologous factor; Kir, inward rectifier K+ channel; PP2A-C, catalytic subunit of
protein phosphatase 2A; Slmap, sarcolemmal membrane-associated protein.

any of the six other heterologously expressed (in HEK-293
cells) paired phosphosilent or phosphomimetic NaV1.5 channels (Fig. S3 and Table 3). Taken together, therefore, these
analyses suggest a key role for phosphorylation at S664-671 in
regulating the voltage dependence of NaV1.5 channel activation and peak INa density, whereas the functional impact of the
other phosphorylation sites most likely involves more complex mechanisms.
Lorenzini et al.
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Protein

The S664 and S667 phosphorylation sites regulate the voltage
dependence of current activation, whereas S671 regulates the
peak INa density
To decipher the respective contributions of the S664, S667, T670,
and S671 phosphorylation sites in regulating the voltage dependence of current activation and peak INa density, each of
these serine/threonine residues was mutated individually to
alanine or glutamate, and the densities and properties of INa
Journal of General Physiology
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produced by the single phosphosilent or phosphomimetic channel
mutants, coexpressed transiently with the accessory NaVβ1 subunit in HEK-293 cells, were determined. These analyses showed
that the voltage dependences of activation of the NaV1.5-S664
(Fig. 4 A) and NaV1.5-S667 (Fig. 4 B) phosphomutant channels are
significantly (P < 0.001) shifted toward depolarized potentials
Lorenzini et al.
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Figure 2. NaV1.5 amino acid sequence coverage and localization of 42 NaV1.5 phosphorylation sites in mαNaVPAN-IPs from sham and TAC mouse left
ventricles. Covered sequence and MS-identified phosphorylation sites are highlighted in yellow and red, respectively; transmembrane segments (S1-S6) in
each domain (I–IV) are in bold and underlined in black; and loops I, II, and III correspond to interdomains I–II, II–III, and III–IV, respectively. The identification of
peptides differing by the presence or absence of a glutamine (Q) at position 1080 ascertains the expression of two NaV1.5 variants: the Q1080 variant
corresponds to UniProt reference sequence K3W4N7, and the Q1080del variant corresponds to UniProt reference sequence Q9JJV9. Two phosphorylation site
locations are possible at amino acids S1056-T1058 (in green). C-TERM, C terminus; N-TERM, N terminus.

compared with the WT channels, whereas no changes were
observed with the NaV1.5-T670 or NaV1.5-S671 phosphomutant channels (Fig. 4, C and D; see detailed properties and
statistics in Table 4). Of note, the ∼6-mV shifts observed with
the NaV1.5-S664A and NaV1.5-S667A single phosphosilent
channels were twofold smaller than the ∼10-mV shift obtained
Journal of General Physiology
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Table 2. Phosphorylation sites, phosphopeptides, and site-discriminating ions identified in immunoprecipitated NaV1.5 proteins from sham and TAC
mouse left ventricles using MS
Phosphopeptide sequence

m/z
(charge)

−10lgP
score

b
Ion

Phospho
b ion

y
Ion

Phospho
y ion

TAC/
sham
ratio

S12

9-GTS(pS)FRR

560.279
(+2)

21.6

b3
(+1)

(-)

y3

(-)

1.2
(n = 1)

S36

35-G(pS)ATSQESR

616.279
(+2)

32.1

b1

(-)

y7

(-)

1.3
(n = 1)

S42

35-GSATSQE(pS)REGLPEEEAPRPQLDLQASK

887.947
(+4)

73.1

b7
(+1)

(-)

y19 y21 (+2)
(+2)

1.5 ±
0.03
(n = 3)

S39 + S42

35-GSAT(pS)QE(pS)REGLPEEEAPRPQLDLQASK

907.937
(+4)

68.4

b4
(+1)

(-)

y19 y21
(+2)

1.2 ±
0.12
(n = 2)

S457 (+ S459 or
S460)

452-GVDTV(pS)RSSLEMSPLAPVTNHER

957.782
(+3)

77.1

b5
(+1)

b7 (−98)
(+2)

y14 (-)
(+1)

1.1 ±
0.09
(n =
10)

S459 + S460

452-GVDTVSR(pS)(pS)LEMSPLAPVTNHER

958.117
(+3)

41.5

b7
b11 (+2)
(+2)

y12 (-)
(+1)

1.2
(n = 1)

S460

459-S(pS)LEMSPLAPVTNHER

1039.003
(+2)

61.2

b1
(+1)

b4 (+1)

y14 (-)
(+1)

1.0 ±
0.05
(n =
18)

S483

481-RL(pS)SGTEDGGDDRLPK

561.038
(+4)

52.4

b2

b3

y13 (-)
(+2)

1.0 ±
0.03
(n =
10)

S484

482-LS(pS)GTEDGGDDR

759.319
(+2)

45.7

b2

(-)

y9 (-)
(+1)

1.2 ±
0.07
(n =
12)

T486

484-SG(pT)EDGGDDRLPK

628.973
(+3)

21.9

b1

b5

y8 (-)
(+2)

1.2
(n = 1)

S483 + S484

480-KRL(pS)(pS)GTEDGGDDRLPK

536.476
(+5)

63

b3

(-)

y12 (-)
(+2)

1.3 ±
0.04
(n =
19)

S497

482-LSSGTEDGGDDRLPK(pS)DSEDGPR

732.845
(+4)

60.2

b12 (-)
(+2)

y7
y12
(+1)

1.3 ±
0.07
(n = 7)

S483 + S497

481-RL(pS)SGTEDGGDDRLPK(pS)DSEDGPR

791.862
(+4)

40.1

b2

b3 (−98)

y6 y12 (+2)
(+1)

0.7
(n = 1)

S484 + S497

482-LS(pS)GTEDGGDDRLPK(pS)DSEDGPR

1003.448
(+3)

54.8

b2
(+1)

b3

y7
y12 (+2)
(+1)

1.7 ±
0.04
(n = 2)

S499

497-SD(pS)EDGPR

586.245
(+2)

42

b2

b5

y4 y6
(+1)

1.4 ±
0.17
(n = 3)

S510

505-ALNQL(pS)LTHGLSR

573.643
(+3)

51.8

b4
(+1)

(-)

y7
(-)
(+1)

0.9 ±
0.03
(n = 3)

S516

505-ALNQLSLTHGL(pS)R

573.644
(+3)

46.7

b9

(-)

y1
(-)
(+1)

0.9
(n = 1)

S525

524-S(pS)RGSIFTFR

489.584
(+3)

40.7

b1
(+1)

(-)

y8 (-)
(+2)

0.8 ±
0.09
(n = 3)
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Table 2. Phosphorylation sites, phosphopeptides, and site-discriminating ions identified in immunoprecipitated NaV1.5 proteins from sham and TAC
mouse left ventricles using MS (Continued)
Phosphorylation
site(s)

Phosphopeptide sequence

m/z
(charge)

−10lgP
score

b
Ion

Phospho
b ion

y
Ion

S539

536-DQG(pS)EADFADDENSTAGESESHR

921.701
(+3)

70.9

b3
(+1)

b5 (+1)

y14 (-)
(+1)

1.5 ±
0.09
(n = 9)

S549

534-RRDQGSEADFADDEN(pS)TAGESESHR

769.579
(+4)

55.3

b15 (-)
(+2)

y9 (-)
(+1)

3.2
(n = 1)

S560

559-T(pS)LLVPWPLR

745.921
(+2)

30.2

b1

b4

y8 (-)
(+1)

1.0
(n = 1)

S571

569-RP(pS)TQGQPGFGTSAPGHVLNGK

911.466
(+3)

55.2

b1
(+1)

b7 (+1), b7 y19
(+2)

S581

569-RPSTQGQPGFGT(pS)APGHVLNGK

683.856
(+4)

48.5

b12 (-)
(+2)

y8 (-)
(+2)

0.9
(n = 1)

S593

591-RN(pS)TVDCNGVVSLLGAGDAEATSPGSHLLR

841.660
(+4)

71.7

b2

b3

y16 (-)
(+1)

0.8 ±
0.05
(n = 4)

S664

662-AL(pS)AVSVLTSALEELEESHRK

936.506
(+3)

60.6

b2
(+1)

b5 (+1)

y18 (-)
(+2)

1.0 ±
0.04
(n =
28)

S667

662-ALSAV(pS)VLTSALEELEESHR

817.416
(+3)

64.1

b5
(+1)

b7 (+1)

y13 (-)
(+1)

0.9 ±
0.06
(n =
12)

T670

662-ALSAVSVL(pT)SALEELEESHRK

702.629
(+4)

54.3

b7
(+1)

(-)

y12 (-)
(+2)

1.1 ±
0.1
(n = 4)

S671

662-ALSAVSVLT(pS)ALEELEESHRK

702.629
(+4)

63.2

b9
b10 (+2)
(+2)

y11 (-)
(+2)

1.7 ±
0.17
(n =
12)***

S664 + S667

662-AL(pS)AV(pS)VLTSALEELEESHRK

886.771
(+3)

58.8

b2

b3

y15 y18
(+2)

1.1 ±
0.05
(n =
18)

S664 + T670

662-AL(pS)AVSVL(pT)SALEELEESHR

844.072
(+3)

59.3

b2
(+1)

b5 (+1),
b8 (+1)

y11 (-)
(+1)

1.0 ±
0.14
(n = 3)

S664 + S671

662-AL(pS)AVSVLT(pS)ALEELEESHR

844.072
(+3)

58.3

b2
(+1)

b5 (+1), b9 y10 (-)
(+2)
(+1)

1.8 ±
0.13
(n = 9)
***

S667 + T670

662-ALSAV(pS)VL(pT)SALEELEESHRK

722.621
(+4)

54.1

b5
(+1)

b8

y12 (-)
(+2)

1.2 ±
0.37
(n = 4)

S667 + S671

662-ALSAV(pS)VLT(pS)ALEELEESHR

844.073
(+3)

60.5

b5
(+1)

b8 (+1),
b9

y10 (-)
(+1)

1.4 ±
0.17
(n = 7)
**

T999

993-KPAALA(pT)HSQLPSCIAAPR

824.114
(+3)

48.8

b6
(+1)

(-)

y12 (-)
(+1)

0.8
(n = 1)

S1001

1001-(pS)QLPSCIAAPR

503.591
(+3)

32.6

(-)

b2 (+1)

y8 (-)
(+1)

1.0 ±
0.11
(n = 4)

(-)

TAC/
sham
ratio

0.8 ±
0.03
(n =
19)
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Table 2. Phosphorylation sites, phosphopeptides, and site-discriminating ions identified in immunoprecipitated NaV1.5 proteins from sham and TAC
mouse left ventricles using MS (Continued)
Phosphorylation
site(s)

Phosphopeptide sequence

m/z
(charge)

−10lgP
score

b
Ion

S1005

993-KPAALATHSQLP(pS)CIAAPRSPPPPEVEKAPPAR

702.389
(+6)

71.4

b11 (-)
(+2)

y18 y21 (+2)
(+2)

0.8 ±
0.16
(n = 2)

S1012

1012-(pS)PPPPEVEK

759.405
(+2)

42.3

(-)

y8 (-)
(+1)

0.9 ±
0.03
(n =
17)

S1056 and/or
T1058

1030FEEDKRPGQGTPGDTEPVCVPIAVAESDTDDQEEDEENSLGTEEEESSK
(1 Phospho)

1230.559
(+5)

57.3

b24 (-)
(+2)

y11 (-)
(+1)

1.8 ±
0.04
(n = 5)

T1105

1097-AWSQVSET(pT)SSEAEASTSQADWQQER

1070.132
(+3)

64.3

b8
(+1)

b9

y12 (-)
(+1)

1.1
(n = 1)

S1107

1097-AWSQVSETTS(pS)EAEASTSQADWQQER

1070.135
(+3)

69.9

b10
(+1)

b15 (+1)

y14 (-)
(+1)

1.2
(n = 1)

S1138

1136-ED(pS)YSEGSTADMTNTADLLEQIPDLGEDVKDPEDCFTEGCVR

1312.582
(+4)

44.7

(-)

b3 (+1)

y23 (-)
(+2)

1.3 ±
0.01
(n = 2)

T1809

1809-(pT)QFIEYLALSDFADALSEPLR

903.451
(+3)

54.8

(-)

b1, b2 (+1) y14 (-)
(+1)

0.8
(n = 1)

S1937

1933-QQAG(pS)SGLSDEDAPER

978.430
(+2)

60.1

b4
(+1)

(-)

y11 (-)
(+1)

1.3
(n = 1)

S1964

1964-(pS)GPLSSSSISSTSFPPSYDSVTR

885.752
(+3)

50.3

(-)

b1 (+1), b4 y14 (-)
(+1)
(+1)

1.2 ±
0.11
(n = 3)

S1969

1964-SGPLS(pS)SSISSTSFPPSYDSVTR

885.753
(+3)

56.9

b5

b6 (+2)

y14 (-)
(+1)

1.0 ±
0.04
(n = 3)

S1971

1963-RSGPLSSS(pS)ISSTSFPPSYDSVTR

937.787
(+3)

48.5

b8
(+1)

(-)

y14 (-)
(+1)

0.9 ±
0.09
(n = 3)

S1973

1964-SGPLSSSSI(pS)STSFPPSYDSVTR

885.750
(+3)

61.8

b9
(+1)

b10 (+2)

y13

(-)

0.9 ±
0.02
(n = 6)

S1974

1964-SGPLSSSSIS(pS)TSFPPSYDSVTR

885.750
(+3)

61.8

b10

(-)

y12 (-)
(+1)

0.9 ±
0.03
(n = 2)

S1989

1987-AT(pS)DNLPVR

641.324
(+2)

37.7

b2

b5

y6 (-)
(+1)

0.8 ±
0.07
(n = 2)

S2011

2002-SEDLADFPP(pS)PDRDR

675.975
(+3)

38.8

b7
(+1)

(-)

y5
y8
(+2)

1.0 ±
0.05
(n =
15)

Phospho
b ion

b1 (+1)

y
Ion

Phospho
y ion

TAC/
sham
ratio
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The site-discriminating ions observed in MS/MS spectra of each annotated NaV1.5 (UniProt reference sequence K3W4N7) phosphopeptide support the
assignment of the indicated phosphorylation site(s). The −10lgP scores attest to the quality of peptide identification. The manually verified charge state of
unphosphorylated and phosphorylated site-discriminating b and y ions is reported in parentheses. (-) indicates that the ion was not detected. Mean ± SEM
phosphopeptide abundance ratios in TAC left ventricles (n = 5) versus sham left ventricles (n = 4) mαNaVPAN-IPs were calculated from n phosphopeptide(s).
**, P < 0.01; ***, P < 0.001; Mann-Whitney test. m/z, mass-to-charge ratio.

with the NaV1.5-S664-671A quadruple phosphosilent channel,
suggesting that the effects at S664 and S667 are additive.
Regarding the analysis of the peak I Na densities, only the
Lorenzini et al.
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Na V 1.5-S671E phosphomimetic channel showed a significant (P < 0.05) decrease, compared with the WT channel
(Fig. 4 H), whereas no significant differences were observed
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with any of the other single phosphomutant channels (Fig. 4,
E–G).
Because phosphorylation at S671 was found to be increased in
the TAC, compared with the sham, mαNaVPAN-IPs (Fig. 1 D),
and because it was previously suggested that phosphorylation of NaV1.5 may mediate increased INaL in heart failure
(Wagner et al., 2006; Maltsev et al., 2008; Koval et al., 2012;
Aiba et al., 2013; Toischer et al., 2013; Glynn et al., 2015),
Lorenzini et al.
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Figure 3. The phosphorylation sites at positions S664-671 regulate the voltage dependence of current activation and peak INa density. (A) Representative whole-cell voltage-gated INa recorded 48 h following transfection of HEK-293 cells with NaV1.5-WT + NaVβ1 (black), NaV1.5-S664-671A + NaVβ1
(blue), NaV1.5-S664-671E + NaVβ1 (red), or NaV1.5-S664-671D + NaVβ1 (green) using the protocols illustrated in each panel. Scale bars are 1 nA and 2 ms.
(B) Voltage dependences of current activation and steady-state inactivation. The voltage dependence of current activation is shifted toward depolarized
potentials in cells expressing the NaV1.5-S664-671A or NaV1.5-S664-671E quadruple phosphomutants compared with cells expressing NaV1.5-WT or the
NaV1.5-S664-671D quadruple phosphomimetic channels. (C) Mean ± SEM peak INa densities plotted as a function of test potential. The peak INa density is
reduced in cells expressing the NaV1.5-S664-671E mutant compared with cells expressing NaV1.5-WT. (D–F) Mean ± SEM times to peak (D), fast (τfast; E), and
slow (τslow; F) inactivation time constants plotted as a function of test potential. The times to peak, τfast, and τslow are higher in cells expressing the NaV1.5S664-671A or NaV1.5-S664-671E quadruple phosphomutants than in cells expressing NaV1.5-WT or NaV1.5-S664-671D. Current densities, time- and voltagedependent properties, and statistical comparisons across groups are provided in Fig. S3 and Table 3. GNa, sodium conductance.

additional voltage-clamp experiments were designed to test
whether phosphorylation at S671 regulates INaL. These analyses
showed that none of the single mutations at S671 or quadruple mutations at S664-671 affect TTX-sensitive I NaL
density in HEK-293 cells (Fig. S4). Altogether, therefore,
these analyses suggest that phosphorylation at S664 and
S667 shifts the voltage dependence of current activation
toward hyperpolarized potentials in a cumulative manner,
Journal of General Physiology
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Table 3. Current densities and properties of NaV1.5 channels mutant for the phosphorylation clusters in transiently transfected HEK-293 cells
INa (pA/pF) Time to peak Time course of inactivation
(ms)
τfast (ms)

τslow
(ms)

Afast/
Aslow

Voltage-dependence
of activation

Voltage-dependence Recovery from
of inactivation
inactivation

V1/2 (mV)

V1/2 (mV)

k (mV)

k (mV)

τrec (ms)

−130.8 ±
13.1 (25)

0.60 ± 0.01
(19)

0.72 ± 0.02
(18)

3.6 ± 0.2
(18)

15.5 ± 1.0 −45.7 ± 0.6
(18)
(19)

6.8 ± 0.2 −88.3 ± 0.6 4.9 ± 0.1 8.7 ± 0.6 (19)
(19)
(19)
(19)

NaV1.5-S3642A

−115.7 ± 11.2 0.63 ± 0.02
(35)
(19)

0.75 ± 0.02
(19)

3.6 ± 0.2
(19)

13.3 ± 1.0 −44.7 ± 0.6
(19)
(19)

6.7 ± 0.1 −86.5 ± 0.8 4.9 ± 0.1 7.1 ± 0.6 (18)
(19)
(19)
(19)

NaV1.5-S3642E

−92.2 ± 11.4 0.59 ± 0.02
(31)
(19)

0.72 ± 0.02
(17)

3.5 ± 0.2
(17)

13.6 ± 1.9 −45.2 ± 0.6
(17)
(19)

6.6 ± 0.1 −86.1 ± 0.5 4.6 ± 0.1 7.3 ± 0.3 (18)
(19)
(19)
(19)

NaV1.5-S457- −136.5 ±
460A
12.1 (24)

0.60 ± 0.01
(18)

0.75 ± 0.02
(18)

4.6 ± 0.4 15.6 ± 1.2 −45.4 ± 0.7
(18)
(18)
(18)

NaV1.5-S457- −123.3 ±
460E
11.6 (28)

0.60 ± 0.02
(20)

0.74 ± 0.02
(19)

3.7 ± 0.2
(19)

17.5 ± 1.8 −45.2 ± 0.4
(19)
(20)

6.8 ± 0.1 −87.5 ± 0.5 4.7 ± 0.1 8.7 ± 0.4 (19)
(20)
(19)
(19)

NaV1.5-S483- −104.7 ±
486A
11.3 (40)

0.61 ± 0.02
(28)

0.61 ± 0.02
(26)

3.2 ± 0.1
(26)

12.7 ± 1.0 −47.1 ± 0.6
(26)
(28)

6.3 ± 0.2 −89.1 ± 0.7 5.0 ± 0.1 7.1 ± 0.5 (26)
(28)
(28)
(28)

NaV1.5-S483- −117.4 ±
486E
10.4 (29)

0.55 ± 0.02
(19)

0.59 ± 0.02
(16)

2.9 ± 0.2
(16)

14.2 ± 1.2 −48.2 ± 0.6
(16)
(19)

6.3 ± 0.2 −89.6 ± 0.6 4.8 ± 0.1 8.2 ± 0.6 (16)
(19)
(19)
(19)

NaV1.5-S497- −110.5 ±
499A
13.5 (25)

0.62 ± 0.02
(16)

0.76 ± 0.03
(12)

4.6 ± 0.4 18.0 ± 1.4 −44.6 ± 0.6
(12)
(12)
(16)

7.1 ± 0.1
(16)

−88.4 ± 0.7 4.8 ± 0.1 8.8 ± 0.7 (15)
(16)
(16)

NaV1.5-S497- −129.5 ±
499E
13.8 (22)

0.56 ± 0.01
(18)

0.70 ± 0.02
(17)

3.8 ± 0.2
(17)

16.7 ± 1.0 −46.7 ± 0.5
(17)
(18)

7.2 ± 0.1
(18)

−90.2 ± 0.7 4.9 ± 0.1 9.5 ± 0.6 (18)
(18)
(18)

NaV1.5-S664- −109.8 ±
671A
11.8 (19)

0.83 ±
0.02*** (18)

0.89 ±
0.02** (17)

5.5 ± 0.5* 18.1 ± 1.2
(17)
(17)

−35.1 ±
0.6*** (18)

7.3 ± 0.1
(18)

−87.1 ± 0.6 5.4 ± 0.1 8.4 ± 0.4 (18)
(18)
(18)

NaV1.5-S664- −74.5 ±
671E
10.2# (23)

0.80 ±
0.02*** (18)

0.90 ±
0.03* (15)

4.9 ± 0.4 18.8 ± 1.9 −39.1 ±
(15)
(15)
0.4*** (18)

NaV1.5-S664- −92.2 ± 13.2 0.65 ± 0.02
671D
(18)
(14)

0.77 ± 0.03
(12)

3.7 ± 0.2
(12)

15.5 ± 1.7
(12)

−48.7 ± 0.6
(14)

5.9 ± 0.2
(14)

−103.0 ± 8.5 0.62 ± 0.01
NaV1.5S1003-1010A (38)
(19)

0.76 ± 0.02
(19)

4.2 ± 0.2
(19)

7.4 ± 0.7
(19)

−45.3 ± 0.5
(19)

6.5 ± 0.2 −86.6 ± 0.7 6.0 ± 0.2 6.7 ± 0.6 (19)
(19)
(19)
(19)

−99.9 ± 11.9 0.61 ± 0.01
NaV1.5S1003-1010E (23)
(15)

0.74 ± 0.02
(15)

3.9 ± 0.1
(15)

7.8 ± 0.6
(15)

−45.8 ± 0.8
(15)

6.5 ± 0.2 −86.2 ± 0.8 5.6 ± 0.2 6.4 ± 0.5 (13)
(15)
(15)
(15)

−115.0 ± 7.4 0.63 ± 0.01
NaV1.5S1964-1969A (23)
(21)

0.77 ± 0.02
(20)

4.1 ± 0.2
(20)

15.8 ± 0.9 −44.9 ± 0.5
(20)
(21)

6.6 ± 0.2 −87.6 ± 0.5 5.1 ± 0.1
(21)
(21)
(21)

−132.8 ±
NaV1.5S1964-1969E 18.3 (26)

0.81 ± 0.02
(15)

4.0 ± 0.2
(15)

13.9 ± 0.8 −44.1 ± 0.6
(15)
(17)

7.2 ± 0.2 −89.3 ± 0.8 4.9 ± 0.1 9.3 ± 0.8 (15)
(17)
(17)
(17)

0.66 ± 0.02
(17)

7.0 ± 0.2 −90.0 ±
(18)
0.9 (18)

5.2 ± 0.1 9.3 ± 0.5 (18)
(18)

7.0 ± 0.1 −86.1 ± 0.8 5.1 ± 0.1
(18)
(18)
(18)

7.7 ± 0.6 (16)

7.8 ± 0.4 (18)

Whole-cell voltage-gated INa were recorded 48 h following transfection of HEK-293 cells with the WT or the mutant NaV1.5 channels and the NaVβ1 channel
subunit using the protocols described in the Materials and methods section. The peak INa density, time to peak, and time course of inactivation properties
presented were determined from analyses of records obtained on depolarizations to −20 mV (HP = −120 mV). All values are means ± SEMs. The number of
cells analyzed is provided in parentheses. #, P < 0.05 versus NaV1.5-WT, one-way ANOVA followed by Dunnett’s post-hoc test. *, P < 0.05; **, P < 0.01; ***,
P < 0.001 versus NaV1.5-WT; Kruskal-Wallis followed by Dunn’s post-hoc test.

whereas phosphorylation at S671 decreases the peak I Na
density.
The S671 phosphorylation site regulates the cell surface
expression of NaV1.5 channels
Additional cell surface biotinylation experiments in transiently transfected HEK-293 cells were designed to determine
whether the S671 phosphorylation site regulates the cell surface expression of the NaV1.5 channel protein. Interestingly,
these experiments revealed that the cell surface expression
of the NaV1.5-S671E phosphomimetic channel is significantly
(P < 0.001) decreased compared with the WT or the NaV1.5Lorenzini et al.
Mapping of cardiac NaV1.5 channel phosphorylation sites

S671A phosphosilent channels, whereas no differences in
total NaV1.5 protein expression were observed (Fig. 5, A and
B). Importantly, the decrease observed with the phosphomimetic mutant, compared with the phosphosilent mutant,
suggests that not only this channel locus, but also most
probably phosphorylation at this particular site, underlie the
observed decrease in cell surface expression. Together with
the electrophysiological findings, therefore, these biochemical analyses demonstrate a key role for S671 in regulating
the cell surface expression of NaV1.5, and suggest that
phosphorylation at this site decreases the cell surface expression of NaV1.5-encoded channels.
Journal of General Physiology
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Figure 4. The S664 and S667 phosphorylation sites regulate the voltage dependence of current activation, whereas the S671 phosphorylation site
regulates the peak INa density. Currents were recorded as described in the legend to Fig. 3. (A–D) The voltage dependence of current activation is shifted
toward more depolarized potentials in cells expressing NaV1.5-S664A (A), NaV1.5-S664E (A), NaV1.5-S667A (B), or NaV1.5-S667E (B) than in cells expressing
NaV1.5-WT, whereas no significant differences are observed with the NaV1.5-T670 (C) or NaV1.5-S671 (D) phosphomutants. (E–H) The mean ± SEM peak INa
densities are plotted as a function of test potential. The peak INa density is reduced in cells expressing NaV1.5-S671E (H), compared with cells expressing
NaV1.5-WT, whereas no significant differences are observed with the other phosphomutants. Current densities, time- and voltage-dependent properties, and
statistical comparisons across groups are provided in Table 4. GNa, sodium conductance.
Lorenzini et al.
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Table 4. Current densities and properties of NaV1.5 channels mutant for S664, S667, T670, and S671 in transiently transfected HEK-293 cells
INa (pA/pF)

Time to
peak (ms)

Time course of inactivation

Voltage dependence of Voltage dependence
activation
of inactivation

Recovery from
inactivation
τrec (ms)

τfast (ms)

τslow
(ms)

Afast/
Aslow

V1/2 (mV)

k (mV)

V1/2 (mV)

k (mV)

−162.5 ± 18.0 0.62 ± 0.02
(23)
(21)

0.75 ±
0.02 (19)

3.3 ± 0.2
(19)

13.8 ± 1.5
(19)

−45.7 ± 0.6
(21)

6.0 ± 0.2 −85.0 ± 0.6 4.7 ± 0.1
(21)
(21)
(21)

6.0 ± 0.4 (17)

NaV1.5S664A

−145.2 ± 17.4 0.75 ± 0.01*
(24)
(22)

0.82 ±
0.02 (21)

4.1 ± 0.2
(21)

16.7 ± 1.4
(21)

−38.9 ±
0.5*** (22)

6.6 ± 0.1
(22)

−84.0 ± 0.7 4.8 ± 0.1
(22)
(22)

6.6 ± 0.6 (22)

NaV1.5S664E

−133.6 ± 15.4 0.73 ± 0.02
(23)
(19)

0.79 ±
0.03 (14)

3.3 ± 0.2
(14)

11.7 ± 1.1
(14)

−39.0 ±
0.6*** (19)

6.7 ± 0.1
(19)

−83.4 ± 0.8 4.7 ± 0.1
(19)
(19)

6.1 ± 0.5 (19)

NaV1.5S667A

−155.3 ± 14.6 0.75 ± 0.02
(23)
(19)

0.78 ±
0.03 (16)

3.9 ± 0.2
(16)

14.1 ± 1.0
(16)

−39.4 ±
0.5*** (19)

6.3 ± 0.2
(19)

−83.7 ± 0.6 4.9 ± 0.1
(19)
(19)

6.0 ± 0.4 (16)

NaV1.5S667E

−126.7 ± 16.0 0.76 ± 0.02*
(22)
(19)

0.81 ±
0.02 (14)

4.0 ± 0.2
(14)

14.9 ± 1.3
(14)

−39.5 ±
0.7*** (19)

6.6 ± 0.1
(19)

−83.8 ± 0.9 4.7 ± 0.1
(19)
(19)

6.7 ± 0.7 (19)

NaV1.5T670A

−157.2 ± 16.0 0.63 ± 0.02
(19)
(19)

0.64 ±
0.02 (18)

3.0 ± 0.2
(18)

11.2 ± 1.5
(18)

−45.1 ± 0.6
(19)

5.4 ± 0.2
(19)

−86.9 ± 0.9 4.8 ± 0.1
(16)
(16)

8.4 ± 0.6 (14)

NaV1.5T670E

−125.7 ± 10.5 0.59 ± 0.02
(25)
(25)

0.70 ±
0.02 (22)

3.5 ± 0.4
(22)

14.3 ± 1.9
(22)

−46.2 ± 0.7
(25)

6.3 ± 0.2
(25)

−87.7 ± 1.0
(20)

4.6 ± 0.1
(20)

9.8 ± 1.0 (20)

NaV1.5S671A

−130.7 ± 13.7 0.54 ± 0.02
(35)
(34)

0.59 ±
0.02 (25)

2.3 ± 0.1
(25)

10.3 ± 0.9 −44.4 ± 0.5
(25)
(34)

6.5 ± 0.1
(34)

−84.9 ± 0.6 4.5 ± 0.1
(32)
(32)

5.6 ± 0.3 (30)

NaV1.5S671E

−100.6 ±
13.8# (25)

0.65 ±
0.02 (11)

2.7 ± 0.3
(11)

9.9 ± 1.6
(11)

−45.0 ± 0.5
(23)

6.8 ± 0.1
(23)

−86.1 ± 0.5 4.4 ± 0.1
(23)
(23)

6.4 ± 0.3 (21)

0.52 ± 0.01
(23)

Whole-cell voltage-gated INa were recorded 48 h following transfection of HEK-293 cells with the WT or the mutant NaV1.5 channels and the NaVβ1 channel
subunit using the protocols described in the Materials and methods section. The peak INa density, time to peak, and time course of inactivation properties
presented were determined from analyses of records obtained on depolarizations to −20 mV (HP = −120 mV). All values are means ± SEMs. The number of
cells analyzed is provided in parentheses. #, P < 0.05 versus NaV1.5-WT, one-way ANOVA followed by Dunnett’s post-hoc test. *, P < 0.05; ***, P < 0.001
versus NaV1.5-WT; Kruskal-Wallis followed by Dunn’s post-hoc test.

Simulated consequences of phosphorylation on the first
intracellular linker loop of NaV1.5
Like many heavily phosphorylated protein segments (Iakoucheva
et al., 2004; Wright and Dyson, 2015), the first two intracellular
linker loops of NaV1.5 are predicted to be intrinsically disordered.
Conformational heterogeneity is one of the defining hallmarks
of intrinsically disordered regions (IDRs). Heterogeneity is manifest in the amplitude of fluctuations of overall size, shape, and local
secondary structural preferences. There is growing recognition
of sequence specificity whereby the ensembles accessible to an
IDR are governed by the amino acid composition, extent of
phosphorylation, and patterning of residues within the linear sequence. These sequence–ensemble relationships can be uncovered
using all-atom simulations. Given the disparate time scales and
length scales involved, a robust and efficient approach is to use
Markov chain Metropolis Monte Carlo simulations based on the
ABSINTH implicit solvent model as implemented in the CAMPARI
simulation (Vitalis and Pappu, 2009b; Mao et al., 2010; Das and
Pappu, 2013). Here, we used simulations to quantify sequence–
ensemble relationships for the first intracellular linker loop of
human NaV1.5 containing the phosphorylation clusters S457-460,
S483-486, S497-499, and S664-671 identified by MS. For our
simulations, we used segments between 30 and 40 residues in
length, containing each cluster in an approximately central position (441-480 for S457-460, 465-501 for S483-486, 481-515 for
S497-499, 651-684 for S664-671). For each cluster, we performed
Lorenzini et al.
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simulations for the WT sequence, as well as phosphomimetic
mutations where serine(s)/threonine(s) are replaced with glutamate(s). The results of simulations were analyzed using the device
of internal scaling plots. These plots quantify the variation of
ensemble-averaged distances between residues i and j as a function of sequence separation |j-i|. Multiple pairs of residues contribute to a given sequence separation |j-i|. The internal scaling
profiles can be calibrated against reference profiles that pertain to
two kinds of random-coil ensembles. These are designated as EV,
which pertains to profiles extracted for self-avoiding walks, and
FRC, which pertains to profiles extracted for FRCs. Details of these
reference ensembles have been published elsewhere.
Simulations of the 441-480 segment showed that the conformational preferences of the unphosphorylated (WT) peptide
are akin to those of the FRC reference (Fig. 6 A). This implies
that sequence encodes a conformational averaging whereby the
peptide–solvent and peptide–peptide interactions are mutually
compensatory, thereby giving rise to an ensemble that is
maximally heterogeneous. Introduction of phosphomimetic
substitutions S457E, S459E, and/or S460E did not have a large
effect on the ensemble-averaged internal scaling profiles when
compared with the unmodified sequence. We obtained similar
results for the 465-501 segment, which is also largely unaffected by the introduction of the phosphomimetic mutation(s)
of the S483-486 cluster (Fig. 6 B). Conversely, the 481-515 and
651-684 segments were noticeably sensitive to the addition of
Journal of General Physiology
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Discussion
Figure 5. The S671 phosphorylation site regulates the cell surface expression of NaV1.5. (A) Representative Western blots of total (left panel) and
cell surface (right panel) NaV1.5 from HEK-293 cells transiently transfected
with NaV1.5-WT + NaVβ1, NaV1.5-S671A + NaVβ1, or NaV1.5-S671E + NaVβ1.
Samples were probed in parallel with the anti–transferrin receptor (TransR)
and anti-GAPDH antibodies. (B) Mean ± SEM total and cell surface NaV1.5
protein expression in transiently transfected HEK-293 cells (n = 12 in six
different experiments). Expression of NaV1.5 in each sample was first normalized to the TransR protein in the same blot and then expressed relative to
NaV1.5 protein expression (total or cell surface) in cells transfected with
NaV1.5-WT + Navβ1. Relative (mean ± SEM) NaV1.5 cell surface expression is
different (***, P < 0.001, one-way ANOVA followed by the Dunnett’s posthoc test) in cells expressing NaV1.5-WT, NaV1.5-S671A, and NaV1.5-S671E
channels.

the negative charges (Fig. 6, C and D). When unphosphorylated,
these segments preferred conformations that are considerably
more compact than the FRC reference. Upon the introduction of
cumulative phosphomimetic mutations, these segments gradually expanded in the direction of the EV limit.
Taken together, the results suggest that the intrinsic conformational preferences of the WT sequence dictate the extent of
responsiveness of the conformational ensemble to multisite
phosphorylation. Sequence stretches that have an intrinsic
preference for FRC-like conformations are relatively insensitive
to phosphomimetic substitutions of serine/threonine residues.
This insensitivity has been quantified for IDRs that undergo
multisite phosphorylation (Martin et al., 2016). In contrast, sequences that have an intrinsic preference for compact conformations become responsive to phosphomimetic substitutions.
This would appear to derive from the increased fraction of
charged residues (FCR; which engenders preferential solvation)
Lorenzini et al.
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The results presented here provide a novel, detailed phosphorylation map of the native mouse left ventricular NaV1.5 channel
protein, and identify the functional roles of three of these
phosphorylation sites in regulating the expression and gating
properties of NaV1.5-encoded channels. The highly phosphorylated S664 and S667 regulate the voltage dependence of channel
activation in an additive manner, whereas S671, in which
phosphorylation is increased in TAC mouse left ventricles, regulates NaV1.5 cell surface expression and peak INa density. No
additional roles could be assigned to the other clusters of NaV1.5
phosphorylation sites, suggesting additional complexity in the
mechanisms mediating the phosphorylation-dependent regulation of cardiac NaV1.5 channels.
Phosphorylation map of native mouse left ventricular
NaV1.5 channels
The present phosphoproteomic analysis confidently identified a
total of 42 native phosphorylation sites in the NaV1.5 channel
protein purified from mouse left ventricles, of which 19 are
novel (Table S2). 17 of these sites were also found to be phosphorylated in heterologously expressed human NaV1.5 channels
(Herren et al., 2015), suggesting that about half of this phosphorylation pattern is conserved among species (mouse and
human) and cellular systems (native channels in left ventricles
and recombinant channels in HEK-293 cells), whereas the others
may be associated with more specific and/or localized regulation. Among the sites identified, only six were previously suggested to be the targets for specific kinases using in silico and/or
in vitro analyses: S36 and S525 were attributed to the regulation
by PKA; S484 and S664 were assigned to the serum- and
glucocorticoid-inducible kinase 3 (SGK3); and S516 and S571
were ascribed to CaMKII (reviewed in Marionneau and Abriel,
Journal of General Physiology
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and electrostatic repulsions (Mao et al., 2010). The FCR and the
net charge per residue are known to be direct determinants of
the conformational preferences of IDRs (Holehouse and Pappu,
2018). Both the 441-480 and 465-501 segments have a higher FCR
than the 481-515 and 651-684 segments. The addition of a single
negative charge would lead to a greater percentage increase in
the FCR of the 481-515 and 651-684 segments than it would for
the 441-480 and 464-501 segments. As the latter are already
expanded, additional charges do not have a large impact on the
conformational preference. The more compact starting point of
the former allows the phosphomimetic mutations to have a
greater effect. While the results for three of the clusters were
consistent with the experimental data, those for the S497-499
cluster present an apparent inconsistency. These observations
suggest that the ability of this segment to expand due to the
addition of charge is not connected to channel gating. Together
with the electrophysiological analyses, therefore, these simulations suggest that the effect of phosphorylation at S664 and
S667 on the voltage dependence of channel activation is mediated
by the expansion of the area containing the phosphorylation sites
and that this expansion is likely to regulate channel activation
allosterically.
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2015). In marked contrast, several previously described phosphorylation sites were not detected in the present study, including the PKA-dependent S528, the CaMKII-associated T594,
the PKC-dependent S1506, the adenosine monophosphate–
activated protein kinase (AMPK)–dependent T101 (Liu et al.,
2019), and the six Fyn-dependent tyrosines (Ahern et al.,
2005; Iqbal et al., 2018). Although these latter sites have never
been identified in native cardiac tissues and may simply not
exist in the myocardium, it is also possible that the MS detection
of these sites here was prevented because of technical limitations. Indeed, a few cytoplasmic regions of the channel were
not covered in our analysis, most probably because of the
presence of too many, or on the contrary not enough, surrounding tryptic cleavage sites (see regions not highlighted in
Fig. 2). These areas comprise a total of 24 serine/threonine/tyrosine residues, including T101 and S1506, which may, therefore, have been missed. Additionally, the low levels of threonine
and tyrosine phosphorylation, compared with phosphoserines,
may have limited the identification of phosphothreonines and
phosphotyrosines (Johnson and White, 2012). Overall, of the 188
cytoplasmic serine/threonine/tyrosine residues in NaV1.5, 42
(22%) are phosphorylated, and 24 (13%) are not identified in the
MS data acquired.
Strikingly, and consistent with previous studies from our
laboratory (Marionneau et al., 2012b; Burel et al., 2017) and the
Bers group (Herren et al., 2015), the results obtained and presented here again revealed that the first intracellular linker loop
of NaV1.5 is a hot spot for phosphorylation, with a total of 21 sites
identified. Comparisons of the relative abundances of the
Lorenzini et al.
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phosphopeptides identified three highly abundant (and highly
phosphorylated) clusters of phosphorylation sites in the first
intracellular linker loop of NaV1.5 in mouse left ventricles. Retrospectively, it is interesting to note that these most abundant
phosphorylation sites were already detected in previous less
sensitive MS analyses from our laboratory (Marionneau et al.,
2012b; Burel et al., 2017; see Table S2). The simplest interpretation of these findings is that these three phosphorylation
clusters, at positions S457-S460, S483-T486, and S664-S671, are
likely involved in regulating the basal and/or gating properties
of native cardiac NaV1.5 channels. Conversely, the other phosphorylation sites, with lower stoichiometries, may play spatially
or temporally distinct roles in the physiological or more pathophysiological regulation of channel expression or gating.
This suggestion is highlighted for residue S671, for example,
which is substantially (10-fold) less phosphorylated than the
nearby S664 and S667 residues in WT mouse left ventricles,
but is (twofold) up-regulated in TAC left ventricles. Remarkably, this MS analysis also revealed that the vast majority of
identified phosphorylation sites (at least 26) are clustered,
suggesting concomitant phosphorylation and roles in regulating channel expression and/or function. Unexpectedly,
however, except for S664, S667, and S671, no apparent effects
of phosphomimetic or phosphosilent mutations were observed on heterologously expressed (in HEK-293 cells) NaV1.5
current densities or biophysical properties, suggesting a
greater complexity than anticipated in the mechanisms contributing to phosphorylation-dependent regulation of NaV1.5
channels.
Journal of General Physiology
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Figure 6. Simulations of phosphorylation of
segments of the first intracellular linker loop
of NaV1.5. The sequential distance between a
pair of residues is on the x axis, and the average
spatial distance between a pair of residues separated by the specified sequential distance is on
the y axis. <Rij> is the average simulated spatial
distance between all residue pairs separated in
the amino acid sequence by |j-i| residues. The WT
sequences are plotted in black. Phosphorylation
is simulated by single or multiple replacement of
serines/threonines with glutamates (E), and resulting simulations are plotted in gradations of
red. The FRC (in blue) and EV (in purple) limits are
plotted for reference (see text). (A) Sequence
441-480 contains the phosphosites S457, S459,
and S460. (B) Sequence 465-501 contains the
phosphosites S483, S484, and T486. (C) Sequence 481-515 contains the phosphosites S497
and S499. (D) Sequence 651-684 contains the
phosphosites S664, S667, T670, and S671.
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findings are consistent with the additive roles of S664 and S667
in regulating the voltage dependence of channel activation observed in the electrophysiological analyses. Consistent with the
proximity of the S664-671 phosphorylation cluster to the DII
voltage-sensing domain of NaV1.5, which is tightly linked to
channel activation (Varga et al., 2015), our findings suggest that
phosphorylation at S664 and S667 regulates channel activation
through the expansion of the C-terminal extremity of the first
intracellular linker loop of the channel. However, no effects on
channel gating were observed with the S497-499 phosphomimetic mutant, even though the simulation showed an effect on
its ability to expand. This result suggests that the expansion of
this segment, which is more distal to the DII voltage-sensing
domain, does not regulate channel gating.
The S671 phosphorylation site regulates NaV1.5 channel cell
surface expression and peak INa density
The functional analyses also demonstrate that mimicking
phosphorylation at S671 decreases the expression of the NaV1.5
protein at the cell surface, as well as peak INa density in HEK-293
cells. These results suggest that S671 is not phosphorylated in
HEK-293 cells, which is in agreement with the previously published MS analyses (Herren et al., 2015). While the phosphomimetic mutation greatly decreases the cell surface expression
of NaV1.5, the phosphosilent mutation also reduces NaV1.5 surface expression, albeit to a much smaller extent. These confounding results suggest that the regulation mediated by this
locus highly depends on structural changes and that the phosphomimetic mutation affects the cell surface expression of the
channel in part through a change in the structure of the locus.
One could further suggest that the greater effect of the phosphomimetic channel may be caused by additional attributes
common to the phosphate group and the glutamate side chain.
Together, therefore, these findings highlight the novel role of
this locus, and potentially of phosphorylation at this site, in
regulating the cell surface expression of NaV1.5 channels.
Interestingly, the MS analyses also revealed that phosphorylation at S671 is increased in the left ventricles of TAC mice,
suggesting a role in mediating the NaV channel defects associated with heart failure. Because previous studies have suggested
that CaMKII-dependent phosphorylation of NaV1.5 may constitute one of the molecular mechanisms mediating the increased
INaL in heart failure (Wagner et al., 2006; Maltsev et al., 2008;
Koval et al., 2012; Aiba et al., 2013; Toischer et al., 2013; Glynn
et al., 2015), this finding prompted us to examine the INaL generated by the phosphosilent and phosphomimetic NaV1.5 mutants at position 671. Our results herein appeared negative,
although it cannot be excluded that this regulation may require a
specific molecular and cellular environment that is not recapitulated in HEK-293 cells. Additionally, and to our surprise, no
changes in phosphorylation at S571 were observed in our TAC
model, in contrast with previous findings in nonischemic human
heart failure (Koval et al., 2012) and in several animal models of
heart disease (Koval et al., 2012; Toischer et al., 2013; Glynn
et al., 2015). These seemingly disparate findings may reflect
technical and/or experimental differences, including differences
in the models used and/or stages of disease.
Journal of General Physiology
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The S664 and S667 phosphorylation sites regulate the voltage
dependence of NaV1.5 channel activation
The electrophysiological analyses presented here identified key
roles of S664 and S667 in regulating the voltage dependence of
NaV1.5 channel activation. Indeed, the data demonstrate that the
voltage dependence of activation of the quadruple phosphosilent
channels at positions S664-671 is shifted toward depolarized
potentials, compared with the WT and the quadruple aspartate
phosphomimetic channels, whereas the quadruple glutamate
phosphomimetic channels display a smaller shift. These findings
are consistent with WT channels being phosphorylated at S664
and S667 in HEK-293 cells, as previously reported (Herren et al.,
2015), and suggest that disruption of phosphorylation at these
sites impacts channel gating.
Further analyses of the roles of each of the four phosphorylation
sites in this cluster revealed the specific involvement of S664 and
S667 in regulating gating, whereas modifying T670 or S671 was
without effects. Interestingly, however, the single glutamate mutations at S664 and S667 produced the same effects as the single
phosphosilent mutations. These observations suggest that the consequences of glutamate substitution, which introduces a single
negative charge with a small hydrated shell, and the addition of a
phosphate group, which introduces two negative charges with a
large hydrated shell (Hunter, 2012), are functionally quite distinct. It
also seems likely that one glutamate at these loci (in single S664 and
S667 phosphomimetic channels) is not sufficient to mimic
phosphorylation and that multiple glutamates (i.e., in the
quadruple phosphomimetic channel) only partially mimic
phosphorylation. The fact that the shifts induced by the single
phosphosilent mutations are half the shift generated by the
quadruple phosphosilent mutation further supports this hypothesis and suggests that regulation involving these two sites
is cumulative and most likely concomitant. Nevertheless, further investigations, aimed at demonstrating the role of
phosphorylation, rather than any other structural determinants associated with this locus, are certainly warranted. In
this regard, our findings are also in accordance with previous
data reporting the role of SGK3 in shifting the voltage dependence of channel activation toward more hyperpolarized
potentials in Xenopus laevis oocytes, whereas the opposite
effect was observed with the NaV1.5-S664A phosphosilent
channel (Boehmer et al., 2003). Although the involvement of
SGK3 and S664 in a shared regulation was not directly shown
in this previous study, it is tempting to speculate that SGK3
may constitute the kinase phosphorylating S664 and S667 and
mediating this regulation.
The effects of phosphorylation were also analyzed using an
all-atom simulations approach to determine how the introduction of negative charges affects the conformational ensemble of
the segments containing the phosphorylation clusters identified
by MS. These simulations demonstrate that the introduction of
negative charges at positions S497-S499 and S664-671 could
expand the structure of the containing segments, whereas no
effects are likely with the segments containing the S457-460 and
S483-486 phosphorylation clusters. Furthermore, for both of the
affected segments, the expansion likely gradually increases with
the cumulative addition of charges. Interestingly, the simulation
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The results presented here raise the interesting and novel
possibility that increased phosphorylation at S671 participates in
decreasing the peak INa often observed in heart failure. Consistent with this suggestion, a recent study by the Remme group,
using superresolution microscopy, showed a reduction in the
size of NaV1.5 clusters in TAC ventricular myocytes without any
changes in NaV1.5 transcript or total protein expression (Rivaud
et al., 2017). Although further studies will be required to determine directly whether these observations are causally linked
to increased phosphorylation at S671, the results here provide
new hints at understanding the molecular basis of the decreased
peak INa in heart failure.
Altogether, the results presented here demonstrate that native mouse ventricular NaV1.5 is highly phosphorylated and that
the mechanisms mediating the phosphorylation-dependent regulation of NaV1.5-encoded channels are site-specific, complex, and
dynamic and lead to diverse physiological and/or pathological
consequences on both channel gating and expression.

21 of 23

Lorenzini et al.
Mapping of cardiac NaV1.5 channel phosphorylation sites

Martin, E.W., A.S. Holehouse, C.R. Grace, A. Hughes, R.V. Pappu, and T.
Mittag. 2016. Sequence determinants of the conformational properties
of an intrinsically disordered protein prior to and upon multisite
phosphorylation. J. Am. Chem. Soc. 138:15323–15335. https://doi.org/10
.1021/jacs.6b10272
Mishra, S., V. Reznikov, V.A. Maltsev, N.A. Undrovinas, H.N. Sabbah, and A.
Undrovinas. 2015. Contribution of sodium channel neuronal isoform
Nav1.1 to late sodium current in ventricular myocytes from failing
hearts. J. Physiol. 593:1409–1427. https://doi.org/10.1113/jphysiol.2014
.278259
Noyes, A.M., A. Zhou, G. Gao, L. Gu, S. Day, J. Andrew Wasserstrom, and S.C.
Dudley. 2017. Abnormal sodium channel mRNA splicing in hypertrophic cardiomyopathy. Int. J. Cardiol. 249:282–286. https://doi.org/10
.1016/j.ijcard.2017.08.071
Pei, Z., Y. Xiao, J. Meng, A. Hudmon, and T.R. Cummins. 2016. Cardiac sodium channel palmitoylation regulates channel availability and myocyte excitability with implications for arrhythmia generation. Nat.
Commun. 7:12035. https://doi.org/10.1038/ncomms12035
Plant, L.D., D. Xiong, J. Romero, H. Dai, and S.A.N. Goldstein. 2020. Hypoxia
produces pro-arrhythmic late sodium current in cardiac myocytes by
SUMOylation of NaV1.5 channels. Cell Rep. 30:2225–2236.e4. https://doi
.org/10.1016/j.celrep.2020.01.025
Remme, C.A., A.A.M. Wilde, and C.R. Bezzina. 2008. Cardiac sodium channel
overlap syndromes: different faces of SCN5A mutations. Trends Cardiovasc. Med. 18:78–87. https://doi.org/10.1016/j.tcm.2008.01.002
Remme, C.A., and C.R. Bezzina. 2010. Sodium channel (dys)function and
cardiac arrhythmias. Cardiovasc. Ther. 28:287–294. https://doi.org/10
.1111/j.1755-5922.2010.00210.x
Rivaud, M.R., E. Agullo-Pascual, X. Lin, A. Leo-Macias, M. Zhang, E. Rothenberg, C.R. Bezzina, M. Delmar, and C.A. Remme. 2017. Sodium
channel remodeling in subcellular microdomains of murine failing
cardiomyocytes. J. Am. Heart Assoc. 6:e007622. https://doi.org/10.1161/
JAHA.117.007622
Schneider, C., R.A. Newman, D.R. Sutherland, U. Asser, and M.F. Greaves.
1982. A one-step purification of membrane proteins using a high efficiency immunomatrix. J. Biol. Chem. 257:10766–10769.
Schubert, B., A.M. VanDongen, G.E. Kirsch, and A.M. Brown. 1989. Betaadrenergic inhibition of cardiac sodium channels by dual G-protein
pathways. Science. 245:516–519. https://doi.org/10.1126/science.2547248
Shang, L.L., A.E. Pfahnl, S. Sanyal, Z. Jiao, J. Allen, K. Banach, J. Fahrenbach,
D. Weiss, W.R. Taylor, A.M. Zafari, and S.C. Dudley Jr. 2007. Human
heart failure is associated with abnormal C-terminal splicing variants in
the cardiac sodium channel. Circ. Res. 101:1146–1154. https://doi.org/10
.1161/CIRCRESAHA.107.152918
Toischer, K., N. Hartmann, S. Wagner, T.H. Fischer, J. Herting, B.C. Danner,
C.M. Sag, T.J. Hund, P.J. Mohler, L. Belardinelli, et al. 2013. Role of late
sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease. J. Mol. Cell. Cardiol. 61:
111–122. https://doi.org/10.1016/j.yjmcc.2013.03.021
Valdivia, C.R., W.W. Chu, J. Pu, J.D. Foell, R.A. Haworth, M.R. Wolff, T.J.
Kamp, and J.C. Makielski. 2005. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart.
J. Mol. Cell. Cardiol. 38:475–483. https://doi.org/10.1016/j.yjmcc.2004.12
.012
Varga, Z., W. Zhu, A.R. Schubert, J.L. Pardieck, A. Krumholz, E.J. Hsu, M.A.
Zaydman, J. Cui, and J.R. Silva. 2015. Direct measurement of cardiac Na+
channel conformations reveals molecular pathologies of inherited
mutations. Circ. Arrhythm. Electrophysiol. 8:1228–1239. https://doi.org/10
.1161/CIRCEP.115.003155
Vassilev, P.M., T. Scheuer, and W.A. Catterall. 1988. Identification of an intracellular peptide segment involved in sodium channel inactivation.
Science. 241:1658–1661. https://doi.org/10.1126/science.2458625
Vitalis, A., and R.V. Pappu. 2009a. ABSINTH: a new continuum solvation
model for simulations of polypeptides in aqueous solutions. J. Comput.
Chem. 30:673–699. https://doi.org/10.1002/jcc.21005
Vitalis, A., and R.V. Pappu. 2009b. Methods for Monte Carlo simulations of
biomacromolecules. Annu. Rep. Comput. Chem. 5:49–76. https://doi.org/
10.1016/S1574-1400(09)00503-9
Wagner, S., N. Dybkova, E.C. Rasenack, C. Jacobshagen, L. Fabritz, P.
Kirchhof, S.K. Maier, T. Zhang, G. Hasenfuss, J.H. Brown, et al. 2006.
Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+
channels. J. Clin. Invest. 116:3127–3138. https://doi.org/10.1172/JCI26620
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Kääb, S., J. Dixon, J. Duc, D. Ashen, M. Näbauer, D.J. Beuckelmann, G.
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Figure S1. IP yields and relative quantification of NaV1.5 peptide abundances from sham and TAC mouse left ventricles (LVs). (A) Representative
Western blots of total lysates and mαNaVPAN-IPs from sham and TAC LVs probed with the anti-NaV1.5 rabbit polyclonal (RbαNaV1.5) and anti-GAPDH mouse
mAbs. (B) Normalization factors used in MS1 and MS2 analyses to correct for technical variabilities in NaV1.5 protein abundance in mαNaVPAN-IPs from sham
and TAC LVs. (C) Distribution of TAC/sham log2-normalized ratios of NaV1.5 peptide spectrum matches. Both biochemical (A) and MS (B and C) analyses of
NaV1.5 IP yields and peptide relative abundance demonstrate low technical variability.
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Figure S2. Conservation of phosphorylation sites in mouse and human NaV1.5. The mouse (reference sequence NP_001240789.1) and human (NP_
000326.2) NaV1.5 sequences are aligned, and phosphorylation sites identified on the mouse sequence and conserved in human are highlighted in red. Two
phosphorylation site locations are possible at amino acids S1056-T1058 (in green). Transmembrane segments (S1-S6) in each domain (I–IV) are in bold and
underlined in black; loops I, II, and III correspond to interdomains I–II, II–III, and III–IV, respectively. The seven phosphorylation clusters analyzed electrophysiologically are boxed in red. C-TERM, C terminus; N-TERM, N terminus.
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Figure S3. Distributions and mean ± SEM membrane potentials for half-activation and half-inactivation, peak INa densities, and time constants of
recovery from inactivation of WT and mutant NaV1.5 channels. Half-activation (A), peak INa densities (B), half-inactivation (C), and time constants of
recovery from inactivation (D) of WT and mutant NaV1.5 channels. Currents were recorded as described in the legend to Fig. 3. The INa densities presented were
determined from analyses of records obtained on depolarizations to −20 mV (HP = −120 mV). #, P < 0.05 versus NaV1.5-WT, one-way ANOVA followed by the
Dunnett’s post-hoc test. ***, P < 0.001 versus NaV1.5-WT, Kruskal-Wallis followed by the Dunn’s post-hoc test. Current densities, time- and voltagedependent properties, and statistical comparisons across groups are provided in Table 3.
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Figure S4. Distributions and mean ± SEM. (A and B) TTX-sensitive INaL densities of quadruple S664-671 (A) and simple S671 (B) NaV1.5 phosphomutants.
TTX-sensitive INaL were evoked during prolonged depolarizations (350 ms at −20 mV; HP = −120 mV) 48 h after transfection of HEK-293 cells with WT (black),
phosphosilent (blue), and phosphomimetic (red) NaV1.5 channels and NaVβ1. No significant differences between mutant and WT channels were observed.

Provided online are three tables and one data file. Table S1 lists echocardiographic parameters of sham and TAC mice before and 5
wk after surgery. Table S2 summarizes NaV1.5 phosphorylation sites identified in the present and previous studies. Table S3 lists
phosphorylation sites, phosphopeptides, and site-discriminating ions identified in coimmunoprecipitated NaVα subunits from sham
and TAC mouse left ventricles using MS. Data S1 lists representative MS/MS spectra of singly or doubly phosphorylated NaV1.5,
NaV1.4, and NaV1.3 tryptic peptides.
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